Recognition, comorbidity, and outcome of DSM-IV bipolar I and II disorders in psychiatric care by Mantere, Outi
Publications of the National Public Health Institute   A   6/2007   
Department of Mental Health and Alcohol Research, 
National Public Health Institute,  
Helsinki, Finland
and
Department of Psychiatry,
University of Helsinki,
Finland
Helsinki 2007
Recognition, Comorbidity,  
and Outcome of DSM-IV  
Bipolar I and II Disorders  
in Psychiatric Care
Outi Mantere
National Public Health Institute,
Department of Mental Health and Alcohol Research,
Helsinki, Finland
and
University of Helsinki,
Department of Psychiatry,
Helsinki, Finland
RECOGNITION, COMORBIDITY, AND OUTCOME OF
DSM-IV BIPOLAR I AND II DISORDERS
IN PSYCHIATRIC CARE
Outi Mantere
Academic Dissertation
To be publicly discussed, with the permission of the Medical Faculty of the University of Helsinki,
in the auditorium of Jorvi Hospital in Espoo, Turuntie 150, on June 8, 2007, at 12 noon.
Helsinki 2007
Publications of the National Public Health Institute
KTL A6/2007
Copyright National Public Health Institute
Julkaisija-Utgivare-Publisher
Kansanterveyslaitos (KTL)
Mannerheimintie 166
FIN-00300 Helsinki, Finland
puh. (09) 4744 1, fax (09) 4744 08
Folkhälsoinstitutet
Mannerheimvägen 166
FIN-00300 Helsingfors, Finland
tel. (09) 4744 1, fax (09) 4744 08
National Public Health Institute (NPHI)
Mannerheimintie 166
FIN-00300 Helsinki, Finland
tel. +358-9-4744 1, fax +358-9-4744 08
ISBN 978-951-740-693-2
ISSN 0359-3584
ISBN 978-951-740-694-9 (pdf)
ISSN 1458-6290 (pdf)
Kannen kuva - cover graphic: Outi Mantere
Painopaikka Edita Prima Oy
Helsinki 2007
Supervisor:
Professor Erkki Isometsä, M.D., Ph.D.
Department of Psychiatry, University of Helsinki, Finland
Department of Mental Health and Alcohol Research,
National Public Health Insitute, Helsinki, Finland
Reviewers:
Assistant Professor Jyrki Korkeila, M.D., Ph.D.
Department of Psychiatry, University of Turku, Finland
and
Assistant Professor Marko Sorvaniemi, M.D., Ph.D.
Department of Psychiatry, University of Turku, Finland
Opponent:
  Professor Raimo K.R. Salokangas, M.D., Ph.D., M.Sc.
Department of Psychiatry, University of Turku, Finland
CONTENTS
TIIVISTELMÄ                                                                                                                     7
ABBREVIATIONS                                                                                                                 9
1.   ABSTRACT                                                                                                                  11
2.   LIST OF ORIGINAL PUBLICATIONS  13
3.   INTRODUCTION                                                       14
4.  REVIEW OF LITERATURE  15
       4.1  Diagnostic boundaries of bipolar disorder I, bipolar disorder II, and major
              depressive disorder                                                                                               15
               4.1.1  Classification and validity of psychiatric disorders                                                     15
               4.1.2  Distinction between bipolar disorder I and II                                                            16
               4.1.3  Mania and hypomania                                                                                       21
               4.1.4  Mixed phase                                                                                               23
               4.1.5  Depressive mixed phase                                                                                    25
               4.1.6  Differences between depressive patients with bipolar or major depressive
                         disorder                                                                                               26
               4.1.7  Stability of diagnosis in mood disorders                                                                  28
               4.1.8  Alternative views of mood disorders                                                                      30
       4.2  Comorbidity of bipolar disorder and major depressive disorder                                                     32
               4.2.1  Definition of the concept                                                                                 33
               4.2.2  Current comorbidity of bipolar disorder                                                                  33
               4.2.3  Comorbidity of bipolar disorder during lifetime                                                           34
               4.2.4  Comorbidity of bipolar disorder compared with major depressive disorder                        36
       4.3  Course and outcome of bipolar disorder                                                                             37
               4.3.1  Methods used to assess outcome in bipolar disorder                                                       37
               4.3.2  Course specifiers                                                                                         38
               4.3.3  Course and outcome of bipolar patients                                                                    39
               4.3.4  Differences between bipolar disorder types I and II in outcome                                          40
       4.4  Epidemiology of bipolar disorder                                                                                    42
               4.4.1  Prevalence of bipolar disorder and bipolar spectrum                                                       42
       4.5  Recognition of bipolar disorder                                                                                     43
               4.5.1  Delay in diagnosis                                                                                        45
               4.5.2  Undiagnosed bipolar disorder                                                                              45
               4.5.3  Differences between recognized and unrecognized bipolar disorder patients                      46
               4.5.4  Consequences of missed diagnosis                                                                         46
               4.5.5  Screening for bipolar disorder                                                                            47
5. AIMS OF THE STUDY                                                                                                      48
 6. METHODS                                                                                                              49
       6.1  General study designs                                                                                               49
       6.2  Screening                                                                                                           50
       6.3  Baseline evaluation                                                                                                 52
               6.3.1  Diagnostic measures                                                                                       52
               6.3.2  Observer and self -report scales                                                                          53
               6.3.3  Other characteristics                                                                                     53
               6.3.4  Assessing comorbidities in Study II                                                                       54
       6.4  Follow-up procedure                                                                                                 54
               6.4.1  Study drop-outs                                                                                           54
               6.4.2  Integration of information into a life chart                                                              55
               6.4.3  Definitions for time periods of life chart                                                               55
               6.4.4  Principal outcome measures                                                                                57
       6.5  Statistical methods                                                                                                 58
 7. RESULTS                                                                                                               59
       7.1  Clinical characteristics of bipolar I and II disorders (Study I)                                                    59
               7.1.1  Analysis of screening                                                                                     59
               7.1.2  Clinical history                                                                                          59
               7.1.3  Missing clinical diagnosis and delays in diagnosis                                                        61
               7.1.4  Current episode and phase                                                                                 61
               7.1.5  Symptom severity                                                                                          61
       7.2  Differences in axis I and II comorbidity between bipolar I and II disorders and
              major depressive disorder (Study II)                                                                              62
               7.2.1  Comorbidity in bipolar disorder versus major depressive disorder                                      62
               7.2.2  Comorbidity in bipolar disorder                                                                           63
       7.3  Clinical predictors of unrecognized bipolar I and II disorders (Study III)                                      64
       7.4  Outcome of bipolar disorder (Study IV)                                                                             65
               7.4.1  Proportion of time in different symptom states during follow-up                                        65
               7.4.2  Factors underlying more time ill                                                                          67
               7.4.3  Other principal outcome measures                                                                          67
               7.4.4  Effect of index phase                                                                                     67
               7.4.5  Effect of a polyphasic episode at intake                                                                  68
               7.4.6  Effect of clinical diagnosis and adequate acute-phase pharmacotherapy at
                         intake on principal outcome measures                                                                   68
               7.4.7  Linear regression models and survival analyses of differences between
                         bipolar I and II patients in the five principal outcome measures                                      69
 8.    DISCUSSION                                                                                                               70
       8.1  Main findings                                                                                                       70
       8.2  Methods                                                                                                             71
               8.2.1  Representativeness of the cohort sample                                                                  71
               8.2.2 Screening                                                                                                  71
               8.2.3 Diagnostic measures                                                                                        72
               8.2.4 Effect of current phase                                                                                    72
               8.2.5 Life chart and definitions of outcome                                                                      73
       8.3  General characteristics of the cohort compared with other cohorts with bipolar
              patients                                                                                                          74
       8.4  Clinical differences between bipolar I and II patients                                                             75
       8.5  Differences in comorbidity between bipolar disorder and major depressive
              disorder                                                                                                          75
       8.6  Recognition of bipolar disorder                                                                                    76
       8.7  Differences in outcome between bipolar disorder I and II                                                          77
               8.7.1  Depressive mixed phases                                                                                   79
       8.8  Contributions to the validity of distinction of bipolar disorder I and II                                      79
9.    CONCLUSIONS AND FUTURE IMPLICATIONS                         81
       9.1  Conclusions                                                                                                         81
       9.2  Clinical implications                                                                                               82
       9.3  Implications for future research                                                                                    83
10.    ACKNOWLEDGEMENTS  84
11.    REFERENCES                                                                                                               86
7Outi Mantere, Kaksisuuntaisen mielialahäiriön tunnistus, muu psykiatrinen sairastaminen ja
ennuste psykiatrisessa erikoissairaanhoidossa
Kansanterveyslaitoksen julkaisuja, A6/2007, 111 sivua
ISBN 978-951-740-693-2; 978-951-740-694-9 (pdf)
ISSN 0359-3584; 1458-6290 (pdf)
http://www.ktl.fi/portal/4043
TIIVISTELMÄ
Tämä tutkimus on osa Kansanterveyslaitoksen ja Helsingin ja Uudenmaan sairaanhoitopiirin
Jorvin sairaalan psykiatrian tulosyksikön kaksisuuntaisen mielialahäiriön seurantatutki-
musta (Jorvi Bipolar Study), jossa seurataan 191 ajankohtaisesta (DSM-IV) mielialajaksosta
kärsivää psykiatrisen erikoissairaanhoidon avohoito- ja sairaalapotilasta.
Tutkimusta varten seulottiin Jorvin psykiatrisessa erikoissairaanhoidossa 1630 potilasta,
joista 490 haastateltiin puolistrukturoidulla haastattelumenetelmällä [Structured Clinical
Interview for DSM-IV disorders, researcher version with psychotic screen (SCID-I/P)].
Tutkimuksessa mukana olevat potilaat (N=191) täyttivät tutkimuksen alussa ajankohtaisen
vakavan masennuksen, manian, hypomanian, sekamuotoisen tai depressiivisen sekamuotoisen
mielialavaiheen kriteerit. Potilaiden oiretila, muut psykiatriset ja somaattiset sairaudet,
hoitavan henkilön antama kliininen diagnoosi, hoito ja itsetuhoisuus kartoitettiin sisäänotto-
vaiheen lisäksi 6kk ja 18kk haastatteluissa. Tämän lisäksi ajankohtaisen ja uusien sairausjak-
sojen ajallinen kesto ja laatu kirjattiin koko 18kk:n seuranta-ajalta. Seuranta-aika jaettiin
kolmea eri toipumisastetta kuvaavaan jaksoon: 1) täydellinen toipuminen, 2) osittainen
toipuminen ja 3) ei toipunut. Toipumista mitattiin myös määrittämällä ajankohtaisen sairaus-
vaiheen ja sairausjakson kesto, aika osittaiseen tai täydelliseen toipumiseen ja aika täydelli-
sestä toipumisesta uusintaan. Verrattaessa kaksisuuntaisen mielialahäiriön tyyppi I ja II
komorbiditeettia vakavasta masennuksesta kärsivien komorbiditeettiin vertailuryhmänä
käytettiin 269 vakavaa masennusjaksoa sairastavaa potilasta Vantaa Depression Studysta.
Tutkimuksessa todettiin, että kaksisuuntainen mielialahäiriö oli huonosti tunnistettu
psykiatrisessa erikoissairaanhoidossa. Niistä kaksisuuntaista mielialahäiriötä sairastavista
potilaista, jotka tarvitsivat akuutisti hoitoa, 39% ei ollut koskaan saanut oikeaa kliinistä
diagnoosia. Erityisesti tyyppi II häiriötä sairastavat potilaat ja naiset olivat huonommin
tunnistettuja. Tunnistaminen näytti tapahtuvan perustuen ajankohtaisesti ilmeneviin ns. klassi-
siin eli maanisiin tai psykoottisiin oireisiin erityisesti sairaalahoitoa vaativissa jaksoissa.
8Kun klassisia oireita ei esiintynyt, kuten tyyppi II sairaudessa mutta myös isossa osassa tyyppi I
sairautta, sairaus oli huomattavasti huonommin tunnistettu. Oikea diagnoosi löytyi tyyppi II
sairaudessa useimmiten vasta kun potilas oli ollut hoidossa pitkään, eivätkä muut yksittäiset
sairauden kuvaan liittyvät tekijät kuin psykoottisuus selittäneet tunnistamista. Näyttää siis,
että mielialahäiriö diagnosoitiin perustuen ajankohtaiseen oirekuvaan, unohtaen pitkittäis-
anamneesin merkitys.
Vaikka tyyppi II mielialahäiriö oli selvästi huonommin tunnistettu kuin tyyppi I, häiriöt
erosivat vain muutamassa muussa kliinisessä piirteessä. Komorbiditeetissa eli muussa
psykiatrisessa sairastamisessa ei ollut merkitseviä eroja. Sen sijaan ne erosivat ennusteessa.
Tyyppi II häiriötä sairastavat potilaat viettivät noin 40% enemmän aikaa masentuneena kuin
tyyppi I häiriötä sairastavat. Tämä johtui siitä, että tyyppi II potilailla oli useammin ainakin
yksi uusi masennusjakso, suurempi osuus uusista vaiheista oli masennuksia ja masennusjak-
sojen tiheys oli suurempi. Sen sijaan yksittäinen masennusjakso kesti tyyppi I ja II häiriötä
sairastavilla potilailla yhtä kauan.
Komorbiditeetti oli vakavassa masennuksessa ja kaksisuuntaisessa mielialahäiriössä laadul-
lisesti jonkin verran erilaista. Ajankohtaisesti jokin akseli I häiriö oli yleisempi vakavassa
masennuksessa kuin kaksisuuntaisessa mielialahäiriössä (69.1% vs. 57.1%) ja ero johtui
erityisesti ahdistuneisuushäiriöistä. Jokin persoonallisuushäiriö oli sairauksissa yhtä yleinen,
mutta vakavassa masennuksessa oli enemmän klusteri A ja C häiriötä, kaksisuuntaisessa
mielialahäiriössä klusteri B:tä.
Viivästyneen tai puuttuvan diagnoosin seuraukset voivat olla vakavia niin yksilölle kuin
yhteiskunnalle. Tämän vuoksi tutkimuksen tulosten perusteella on suositeltavaa seuloa kaksi-
suuntaista mielialahäiriötä erityisesti vakavasti masentuneiden potilaiden joukossa. Kliini-
sen diagnoosin täytyy kuitenkin aina perustua perusteelliseen kliiniseen haastatteluun ja
seurantaan, jossa huomioidaan pitkäaikainen sairauden kulku. Myös muiden psykiatristen
sairauksien esiintyminen kaksisuuntaisessa mielialahäiriössä on yleistä ja huonontaa enti-
sestään sairauden kulkua. Sen vuoksi se vaatii erillistä arviointia, seurantaa ja hoitoa.
Masennusoireiden hoito on erityisen keskeinen haaste, jotta kaksisuuntaisen mielialahäiriön
ennustetta saataisiin parannettua.
Avainsanat: kaksisuuntainen mielialahäiriö, kaksisuuntainen mielialahäiriö tyyppi II,
tunnistaminen, depressiivinen sekamuotoinen jakso, komorbiditeetti, ennuste
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1. ABSTRACT
This study is part of an ongoing collaborative bipolar research project, the Jorvi Bipolar
Study (JoBS). The JoBS is run by the Department of Mental Health and Alcohol Research of
the National Public Health Institute, Helsinki, and the Department of Psychiatry, Jorvi
Hospital, Helsinki University Central Hospital (HUCH), Espoo, Finland. It is a
prospective, naturalistic cohort study of secondary level care psychiatric in- and
outpatients with a new episode of bipolar disorder (BD). The second report (Study II) also
included 269 major depressive disorder (MDD) patients from the Vantaa Depression Study
(VDS). The VDS was carried out in collaboration with the Department of Psychiatry of the
Peijas Medical Care District.
Using the Mood Disorder Questionnaire (MDQ), all in- and outpatients at the Department of
Psychiatry at Jorvi Hospital who currently had a possible new phase of Diagnostic and
Statistical Manual of Mental Disorders, 4th edition (DSM-IV) BD were sought. Altogether,
1630 psychiatric patients were screened, and 490 were interviewed using a semistructured
interview [Structured Clinical Interview for DSM-IV disorders, researcher version with
psychotic screen (SCID-I/P)]. The patients included in the cohort (N=191) had at intake a
major depressive, manic, hypomanic, mixed, or depressive mixed phase of BD. The
demographic characteristics, variables for prior illness history, preceding treatment,
current symptoms, psychiatric and somatic comorbidity, clinical diagnosis, and suicidality
were evaluated at intake and at 6-and 18-month interviews. All available data were
integrated into the form of a graphic life chart based on DSM-IV criteria. Time after the
beginning of the index phase was divided into three periods: 1) mood episode, 2) partial
remission, or 3) full remission. Five principal outcome measures were used: 1) proportion
of time in different symptom states during follow-up, 2) time with full criteria of the
index phase, 3) time with full criteria of the index episode, 4) time to full remission,
and 5) time to recurrence from the beginning of remission.
Based on this study, BD is poorly recognized even in psychiatric settings. Of the BD
patients with acute worsening of illness, 39% had never been correctly diagnosed. The
classic presentations of BD with hospitalizations, manic episodes, and psychotic symptoms
lead clinicians to correct diagnosis of BD I in psychiatric care. When the classic
12
presentations were absent, as in BD II patients, but also a large proportion of BD I
patients, the disorder was less often recognized. Time of follow-up elapsed in psychiatric
care, but none of the clinical features, seemed to explain correct diagnosis of BD II,
suggesting reliance on cross-sectional presentation of illness.
Even though BD II was clearly less often correctly diagnosed than BD I, few other
differences between the two types of BD were detected, except for some differences in the
severity of illness as defined in the diagnostic criteria. BD I and II patients appeared
to differ little in terms of clinical picture or comorbidity, and the prevalence of
psychiatric comorbidity was strongly related to the current illness phase in both types.
At the same time, the difference in outcome was clear. BD II patients spent about 40% more
time depressed than BD I patients. The most important factors explaining this difference
were higher proportions of BD II than BD I patients having depressive phases, the higher
proportion of depressive phases among all phases in BD II, and the higher frequency of
these phases during follow-up, whereas duration of depressive phases per se was equal.
Patterns of psychiatric comorbidity of BD and MDD differed somewhat qualitatively.
Overall, MDD patients were likely to have more anxiety disorders and cluster A personality
disorders, and bipolar patients to have more cluster B personality disorders.
The adverse consequences of missing or delayed diagnosis are potentially serious. Thus,
these findings strongly support the value of screening for BD in psychiatric settings,
especially among the major depressive patients. Nevertheless, the diagnosis must be based
on a clinical interview and follow-up of mood. Comorbidity, present in 59% of bipolar
patients in a current phase, needs concomitant evaluation, follow-up, and treatment. To
improve outcome in BD, treatment of bipolar depression is a major challenge for
clinicians. Patients without clinical diagnosis do not represent the whole bipolar
population and screening is warranted to detect BD for purposes of research.
Keywords: Bipolar disorder, Bipolar disorder type II, recognition, depressive mixed
episode, comorbidity, outcome
13
2. LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following original publications, which are referred to in the
text by Roman numerals I-IV:
I   Mantere O,  Suominen K,  Leppämäki S,  Valtonen H,  Arvilommi P,  Isometsä E.
    The clinical characteristics of DSM-IV bipolar I and II disorders: baseline findings
    from the Jorvi Bipolar Study (JoBS).
Bipolar Disorders 2004;6:395-405.
II  Mantere O, Melartin TK, Suominen K, Rytsälä HJ, Valtonen HM, Arvilommi P,
    Leppämäki S,  Isometsä ET.  Differences in axis  I and  II comorbidity between
    bipolar I and II disorders and major depressive disorder.
Journal of Clinical Psychiatry 2006; 67:584-593.
III Mantere O, Suominen K, Arvilommi P, Valtonen HM, Leppämäki S, Isometsä E.
    The clinical predictors of unrecognized bipolar I and II disorders. Bipolar Disorders. In press.
IV  Mantere O,  Suominen K,  Valtonen HM,  Arvilommi P,  Leppämäki S,  Melartin T,
    Isometsä E. Differences in outcome of  DSM-IV  bipolar I and II disorders. Bipolar Disorders. 
In press.
These articles are reproduced with the kind permission of their copyright holders.
14
3. INTRODUCTION
Bipolar disorder (BD) is a recurrent and chronic illness. Even though the natural course
of some patients includes full recovery after distinct phases, according to the latest
clinical studies, patients spend half of their time in a symptomatic state (Judd et al.,
2003c; Post et al., 2003; Joffe et al., 2004). Even after syndromal recovery, patients all
too often do not reach symptomatic or functional recovery, and practically all patients
encounter affective recurrences. The disorder has a profound influence on functional
outcome, psychosocial factors, and quality of life. The standardized mortality ratio of BD
patients is about 20 (Harris and Barraclough, 1997), and an estimated 25-50% attempt
suicide at least once (Goodwin, 1990; Jamison, 2000; Slama et al., 2004), and 30-75% have
suicidal ideation (Suppes et al., 2001; MacKinnon et al., 2005). Because of the burden of
the illness on the individual, family, and society, BD is among one of the most disabling
disorders in the world (Morselli and Elgie, 2003). In the Global Burden of the Disease
Study (Murray and Lopez, 1997), neuropsychiatric disorders explained 22% of
disability-adjusted life-years (DALYs) in developed countries, and MDD was the 4th and BD
I the 22nd leading course of DALYs worldwide; obviously, the significance of BD would be
far greater if BD II were included together with BD I instead of MDD. The course is
further complicated by an exceptionally high degree of other comorbid psychiatric
disorders, up to 80% during the lifetime according to several studies (McElroy et al.,
2001; Suppes et al., 2001; Dittmann et al., 2002; Henry et al., 2003; Judd et al., 2003b;
Simon et al., 2004a; Bauer et al., 2005a). At the same time, while the effect of treatment
in BD I is well documented, good-quality evidence in BD II is lacking (Hadjipavlou et al.,
2004).
Despite the severity of the illness, BD is poorly recognized. It has been estimated that
systematic evaluation of depressive patients would find twice as many bipolar patients as
found based on clinical diagnosis (Hantouche et al., 1998; Ghaemi et al., 2000; Kiejna et
al., 2006). It appears that the diagnosis of BD is made either during the first year of
treatment or after a delay of 8-10 years (Ghaemi et al., 2000). The delays in diagnosis
are alarmingly long considering the serious burden caused by delayed diagnosis and the
adverse consequences of inappropriate treatment.
To improve the treatment and recognition of BD, more information on the clinical picture
of the disorder, especially BD type II, is needed. Diagnosis is the basis for all
treatment, but reasons for unrecognized BD have not been investigated. Only a few studies
have reported current and lifetime comorbidity or outcome in a cohort with BD I and II
patients, and the results are conflicting and not generalizable. The Jorvi Bipolar Study
(JoBS) is a prospective, naturalistic cohort study of 191 secondary level care psychiatric
out- and inpatients with a new phase of DSM-IV BD. In the JoBS, the predictors of
chronicity, recurrences, and suicidal behavior as well as work and functional disability
are investigated and the adequacy of treatment evaluated. This thesis focuses on the
recognition, clinical picture, comorbidity, and outcome of bipolar patients followed up
for 18 months. 
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4. REVIEW OF THE LITERATURE
4.1 Diagnostic boundaries of bipolar disorder I,
bipolar disorder II, and major depressive disorder
In the current diagnostic manual for psychiatric research, DSM-IV (APA, 1994), as well as
ICD-10 (WHO, 1993), which is the only official diagnostic system for clinical use in
Europe, mood disorders include major depressive disorder (MDD), bipolar disorders (BD)
type I and II, dysthymia, and cyclothymic disorder. BD is further divided into BD type I,
BD type II, and BD not otherwise specified (NOS). The diagnostic boundary between MDD and
BD seems clearer than that between BD I and BD II. This thesis will focus on BD and MDD as
defined in the DSM classification used in psychiatric research worldwide.
4.1.1 Classification and validity of psychiatric disorders
Classification and subtyping of diseases, that is, diagnoses, serve three purposes:
prediction of treatment response, prognosis, and etiologic research. In psychiatry, some
characteristic features of diagnostics set important challenges for defining diagnostic
criteria. Explicit diagnostic criteria since the Diagnostic and Statistical Manual of 
rdMental Disorders, 3  edition (DSM-III) (APA, 1980) have structured clinical practice,
become a norm in research, provided a universal language in teaching, and improved
communication between the users of psychiatric services, caregivers, and society at large
(Kendell and Jablensky, 2003).
In psychiatry, criteria of validity of a diagnosis can be described as follows:
1) antecedent validators (familiar aggregation, premorbid personality, demographic factors,
precipitating factors), 2) concurrent validators (symptom profiles, psychological tests,
biological markers), 3) predictive validators (diagnostic stability over time, outcome,
response to treatment), and 4) delimitation from other disorders (exclusion criteria)
(Kendler, 1980; Kendell and Jablensky, 2003). The biological phenotypes (molecular
genetics, molecular biology, neuroanatomy, neurochemistry, neurophysiology, cognitive
neuroscience) included in the concurrent validators of the previous model are increasingly
the focus of etiological research.
Clearly, the current diagnostic system should be challenged from the viewpoint of
research. If the validity of a categorical disorder is defined as a zone of rarity (zones
where individuals with certain combinations of features are rare), one could argue that no
psychiatric diagnosis is currently valid (Kendell and Jablensky, 2003). Etiological
studies on psychiatric disorders have shown that many different genes contribute to the
etiology of most of psychiatry’s major syndromes and some genes are risk factors for what
16
have until now been regarded as unrelated syndromes (Kendell and Jablensky, 2003). Also,
the same environmental factors contribute to the genesis of several different syndromes. A
fundamental element of research is that the subjects of research can be explicitly
defined. It may be appropriate for most epidemiological research, studies of clinical
course, and clinical trials to be based on syndromes in clinical use without proven
validity; etiologic research, however, needs valid criteria (Kendell and Jablensky, 2003).
In attempting to solve this problem, some researchers suggest new, narrower or broader
borders for mood disorders. Others suggest dimensional measuring of narrow symptoms
instead of syndromes. In personality disorders, a means of considering diagnoses based on
prototype theory from philosophy of mind has been introduced (Westen et al., 2006). This
might prove valuable when describing the way clinicians understand diagnoses; according to
Westen, the clinicians preferred the prototype view to complex comorbidity according to
DSM categories when evaluating individual patients (Westen et al., 2006). The ICD-10
diagnostic system is in most countries used in a prototype way, without the lists of
research criteria applied in Finland.
One feature of a diagnosis is that it is a reduction of a more complex entity to a simpler
one, something apprehensible and manageable. The aim is to characterize the illness
experience as an example of a more general phenomenon, something shared by others, and a
rewarding subject for research (Sadler, 2005). If validity and utility of a diagnosis are
differentiated, it can be said that most current psychiatric diagnoses have great utility
for clinicians (Kendell and Jablensky, 2003). At the same time, diagnostic
characterization involves a movement away from viewing an individual’s illness as a
singular, unique phenomenon. A suffering and needful patient presents a unique failure or
inadequacy of his own personal resources to aid himself (Sadler, 2005). For the patient,
the value and validity of the diagnosis may differ strongly from those for clinicians or
researchers.
4.1.2 Distinction between bipolar disorder I and II
Mania and melancholia are two of the earliest human diseases described, having been
recognized as illnesses since ancient times (Goodwin, 1990; Angst and Marneros, 2001).
Hippocrates (460-337 BC) was the first to systematically describe the two illnesses, and
Aretaeus of Cappadocia in the 1st century thought of them as different images of a single
disease (Angst and Marneros, 2001). In the 18th century, several independent scientists in
Germany, England, and Italy had described melancholia and mania to be longitudinally
associated (Angst and Marneros, 2001), and in the mid-19th century, French researchers
suggested a one illness theory of mania and depression: la folie circulaire by Falret, and
folie à double forme by his student Baillarger (Goodwin, 1990; Angst and Marneros, 2001).
"The father of modern psychiatry", Emil Kraepelin in 1893 distinguished psychotic
illnesses from each other (Angst and Marneros, 2001); his model of mood disorders can be
said to be a one-disease model, including also the foundation for the later development of
spectrum concepts (Goodwin, 1990). Thus, manic-depressive illness had become the first
fully developed disease model in psychiatry, even encompassing psychological and social
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factors (Goodwin, 1990). The German Kleist and Leonhard further distinguished
manic-depressive and recurrent depressive patients (called bipolar and monopolar or
unipolar patients) (Angst and Marneros, 2001), which has been the basis for classificatory
systems in psychiatry since DSM-III (APA, 1980) and ICD-10 (WHO, 1993). However, at least
five mood disorder models still have their supporters (see Section 4.1.8). Schizoaffective
disorder has not been included in these theoretical models.
In the 1970s, a subgroup of BD patients with hypomanic instead of manic phases was
identified (Goodwin et al., 1972; Dunner et al., 1976; Fieve et al., 1984). BD types I and
II have subsequently become separated based on the presence of manic and mixed phases in
BD I and hypomanic phases in BD II (see Sections 4.1.3 and 4.1.4). The distinction has
been largely supported by studies describing increased risk for BD II among relatives of
BD II, while the relatives of patients with BD I have both BD I and II (Gershon et al.,
1982; Coryell et al., 1984; Fieve et al., 1984; Endicott et al., 1985; Andreasen et al.,
1987; Rice et al., 1987; Heun and Maier, 1993; Sadovnick et al., 1994; Kelsoe, 2003).
Otherwise, surprisingly modest differences have been found in studies comparing BD I and
II. The studies are presented in Table 1, and for recent reviews of the differences see
(Berk and Dodd, 2005; Skeppar and Adolfsson, 2006). The differences in sociodemographic
and clinical features are presented in Table 2, differences in comorbidity in Sections
4.2.2 and 4.2.3 and Table 5., and differences in outcome in Section 4.3.4 and Table 6.
Biological studies seem to prefer BD I patients and comparisons between BD and MDD, and
thus, the biological validation of BD I and II remains a subject for future research. The
few studies comparing neurobiological differences between BD I and II thus far seem not to
support distinguishing between these disorders (McGrath et al., 2004). In addition, while
many differences in personality and temperament have been suggested (Berk and Dodd, 2005;
Savitz and Ramesar, 2006; Skeppar and Adolfsson, 2006), the results remain controversial.
Several but contradictory reports of other differences exist. Age at onset has been
described to be either earlier in BD I (Coryell et al., 1989; Tondo et al., 1998; Suppes
et al., 2001; Serretti et al., 2002a; Post et al., 2003) or equal (Judd et al., 2003b). BD
I patients may have a higher proportion of males (Tondo et al., 1998) or gender
distribution may be similar (Suppes et al., 2001; Judd et al., 2003b; Post et al., 2003).
BD I patients have had a higher severity of depressive phases (Serretti et al., 2002a;
Judd et al., 2003b), more hospitalizations (Coryell et al., 1989; Serretti et al., 2002a),
and more psychotic features at intake (Benazzi and Akiskal, 2001; Serretti et al., 2002a;
Akiskal and Benazzi, 2003; Judd et al., 2003b) or during the lifetime (Suppes et al.,
2001). BD II patients have been more (Tondo et al., 1998) or less (Post et al., 2003)
likely to be married, more likely to be divorced (Tondo et al., 1998), more likely to be
employed (Coryell et al., 1987), and more likely to have a higher income (Post et al.,
2003). No difference was detected in other studies in education (Tondo et al., 1998; Judd
et al., 2003b; Post et al., 2003) or marital status (Judd et al., 2003b). BD II patients
were more likely to have a depressive first phase in one study (Tondo et al., 1998), while
another study found no difference (Judd et al., 2003b) and a third study reported
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manic/hypomanic onset more often in BD I and slightly more depressive onsets in BD II
(Suppes et al., 2001). Suicidality has been more prevalent in BD II (Tondo et al., 1998;
Serretti et al., 2002a; Balazs et al., 2003), in BD I (Angst and Marneros, 2001), or
equally prevalent (Coryell et al., 1989; Dalton et al., 2003; Leverich et al., 2003; Post
et al., 2003).
The significance of these differences remains uncertain because of several limitations in
previous studies. First, the cohorts are mostly highly selected, and thus, the results are
hardly generalizable to the majority of patients found in secondary care treatment.
Second, possible confounding factors (age, comorbidity, acute state) have not been
reported or controlled in the analyses. It is not surprising that BD I has more psychotic
features and hospitalizations excluded by definition in hypomanic phases. In addition,
cross-sectional severity of the symptoms is likely to correlate with hospitalization and
psychotic features, and longitudinal severity with many sociodemographic features. Thus,
differences in the severity of the illness cannot be used as strong evidence for the
existence of two separate disorders.
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Table 1. Previous clinical cohorts including BD I and BD II patients
Name/ or Inpatients/    Place of Current Size of the Follow- Diagnostic Comparison Key
place of outpatients sampling mood cohort, up, method of BD I and references
the cohort at intake                                BD I/BD II years                    BD II
                                                         n (%)
National       79.1%/20.9%    Five          Acute        135           20       Schedule        Yes            (Coryell et al.,
Institute                     academic      manic,       (65.5%)/               for                            1989;
of Mental                     centers in    hypomanic,   71                     Affective                      Judd et al.,
Health                        the USA       mixed, or    (34.5%),               Disorders                      2003b;
Collaborative                               major        total 206              and                            Judd et al.,
Depression                                  depressive                          Schizophrenia                  2005;
Study                                       episode                             (SADS),                        Judd et al.,
(CDS)                                                                           Research                       2003c)
                                                                                Diagnostic
                                                                                Criteria (RDC)
Stanley        0%/100%        Four          Not          Varies from   1        Structured      Yes            (Kupka et al.,
Foundation                    academic      reported     239                    Clinical                       2005;
Bipolar                       sites in                   (83.0%)/               Interview for                  Leverich et al.,
Network                       the USA                    49                     DSM-IV Axis                    2003;
                              and one in                 (17.0%),               I Disorders                    McElroy et al.,
                              Netherlands;               total 288 to           (SCID-P)                       2001;
                              added also                 681                    Axis II                        Nolen et al.,
                              self-referral              (78.5%)/               self-rated;                    2004;
                              patients                   187                    DSM-IV                         Post et al.,
                                                         (21.5%)                                               2003;
                                                         total 868                                             Suppes et al.,
                                                                                                               2005)
Systematic     0%/100%        Multicenter   Acute        Varies from   2        Affective       Yes            (Perlis et al.,
Treatment                     study in      manic,       360                    Disorder                       2006b;
Enhancement                   the USA       hypomanic,   (75.8%)/               Evaluation                     Simon et al.,
Program                                     mixed or     115                    (ADE),                         2004b)
for                                         major        (24.2%),               Mini-
Bipolar                                     depressive   total 475,             International
Disorder                                    episode      up to                  Neuro-
(STEP-BD)                                   59.6% of     total 812              psychiatric
                                            patients                            Interview
                                                                                (MINI), DSM-IV
Stanley        0%/100%        Hospitali-    Not          108           2.5      SCID-P,         Yes            (Dittmann
Foundation,                   zation        reported     (74.0%)/               SCID-II,                       et al., 2002)
German                        or                         38                     DSM-IV
cohort                        self-                      (26.0%),
                              referral                   total 146
Henry          100%/0%        Two           Acute        237           No       Diagnostic      No             (Henry et al.,
                              university    hospitali-   (74.5%)/               Interview                      2003)
                              hospitals     zation,      81                     for
                              in France     not          (25.5%),               Genetic
                                            specified    total 318              Studies
                                                                                (DIG), DSM-IV
Sardinia       Not            Several       Not          293           1        Various         Yes            (Baldessarini
               reported       clinical      reported     (65.1%)/               criteria,                      et al., 2003;
                              trials                     157                    no                             Tondo et al.,
                              from mood                  (34.9%),               structured                     1998;
                              disorder unit              total 450              interview                      Tondo et al.,
                              in Sardinia                                                                      2001)
McMaster       0%/100%        Mood          Not          97            3        SCID,           Yes            (Joffe et al.,
Regional                      disorder      reported     (70.3%)/               DSM-IV                         2004)
Mood                          pogram in                  41
Disorder                      Canada                     (29.7%),
Program                                                  total 138
Milan,         87.1%/12.1%    Subjects      Major        863           No       SADS,           Yes            (Serretti
Italy                         combined      depressive   (86.0%)/               DSM-III-R                      et al., 2002a)
                              from          phase        141                    and DSM-IV
                              clinical                   (14.0%),
                              and genetic                total 1004
                              samples from
                              tertiary
                              care in Italy
20
Table 2. Review of the main differences between BD I and BD II in 
patient characteristics and clinical history
   Reported differences
Sociodemographic variables
Gender                        BD II more female  (Tondo et al., 1998)
                              Equal (Judd et al., 2003b; Post et al., 2003; Suppes et al., 2001)
Marital status                Married  BD II>BD I (Tondo et al., 1998), BD I>BD II (Post et al., 2003)
                              Divorced BD II>BD I (Tondo et al., 1998)
                              No difference (Judd et al., 2003b)
Family history of BD          More BD II in families of BD II patients (Andreasen et al., 1987;
                              Coryell et al., 1984; Endicott et al., 1985; Fieve et al., 1984;
                              Gershon et al., 1982; Heun and Maier, 1993; Kelsoe, 2003;
                              Rice et al., 1987; Sadovnick et al., 1994)
Clinical history 
Age at onset, treatment       BD II>BD I (Coryell et al., 1989; Post et al., 2003; Serretti et al., 2002a;
or hospitalization            Suppes et al., 2001; Tondo et al., 1998; Baldessarini et al., 2003)
                              No difference (Judd et al., 2003b)
Total episodes No difference (Serretti et al., 2002a; Judd et al., 2003b)
Depressive phases   BD II>BD I (Serretti et al., 2002a)
Suicidality                   BD I>BD II (Angst and Marneros, 2001)
                              BD II>BD I (Balazs et al., 2003; Serretti et al., 2002a; Tondo et al., 1998)
                              No difference (Coryell et al., 1989; Dalton et al., 2003; Leverich et al., 2003;
                              Post et al., 2003)
Hospitalizations              BD I>BD II (Coryell et al., 1989)
Cross-sectional severity
Psychotic symptoms            BD I>BD II (Akiskal and Benazzi, 2003; Benazzi and Akiskal, 2001; Judd et al., 2003b;
                              Serretti et al., 2002a)
Symptoms scores/              BD I>BD II (Judd et al., 2003b)
severity in depression
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4.1.3 Mania and hypomania
The  mania-specific  DSM-IV  criteria  of  a  manic phase (APA, 1994) include A) a distinct
period of abnormally and persistently elevated, expansive, or irritable mood, lasting at
least 1 week (or any duration if hospitalization is necessary) and B) during the period of
mood disturbance, three (or more) of the following symptoms have persisted (four if the
mood is irritable) and have been present to a significant degree: 1) inflated self-esteem
or grandiosity, 2) decreased need for sleep, 3) more talkative than usual or pressure to
keep talking, 4) flight of ideas or subjective experience that thoughts are racing, 5)
distractibility, 6) increase in goal-directed activity or psychomotor agitation, or 7)
excessive involvement in pleasurable activities that have a high potential for painful
consequences (Table 3).
Table 3. DSM-IV criteria for Manic Episode
A.   A distinct period of abnormally and persistently elevated, expansive, or irritable mood,
     lasting at least 1 week (or any duration if hospitalization is necessary).
B.   During the period of mood disturbance, three (or more) of the following symptoms have persisted
     (four if the mood is only irritable) and have been present to a significant degree:
     1.  inflated self-esteem or grandiosity
     2.  decreased need for sleep (e.g., feels rested after only 3 hours of sleep)
     3.  more talkative than usual or pressure to keep talking
     4.  flight of ideas or subjective experience that thoughts are racing
     5.  distractibility (i.e., attention too easily drawn to unimportant or irrelevant external stimuli)
     6.  increase in goal-directed activity (either socially, at work or school, or sexually) or
         psychomotor agitation
     7.  excessive involvement in pleasurable activities that have a high potential for painful
         consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions,
         or foolish business investments)
C.   The symptoms do not meet the criteria for a Mixed Episode.
D.   The mood disturbance is sufficiently severe to cause marked impairment in occupational functioning
     or in usual social activities or relationships with others, or to necessitate hospitalization to
     prevent harm to self or others, or there are psychotic features.
E.   The symptoms are not due to the direct physiological effects of a substance (e.g. a drug of abuse,
     a medication or other treatment) or a general medical condition (e.g., hyperthyroidism).
Note: Manic-like episodes that are clearly caused by somatic antidepressant treatment (e.g., medication,
     electroconvulsive therapy, light therapy) should not count toward a diagnosis of Bipolar I Disorder.
Diagnosis of bipolar disorder according to the Diagnostic and statistical manual of mental disorders,
Fourth Edition (DSM-IV), Text Revision (American Psychiatric Association, 2000)
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The DSM-IV hypomania-specific criteria for a hypomanic phase (APA, 1994) differ from the
criteria of a manic phase in that the expression "abnormally changed" is omitted from
criterion A, and duration of only 4 days is required (Table 4). Also, hypomania is
differentiated from mania in that the phase must not be severe enough to cause marked
impairment in social or occupational functioning, or to necessitate hospitalization, and
no psychotic features are present. By contrast, the criteria for hypomania also specify
that C) the episode is associated with an unequivocal change in functioning that is
uncharacteristic of the person when not symptomatic and D) the disturbance in mood and the
change in functioning are observable by others. The requirement of three (in euphoric
mood) or four (in irritable mood) B criteria is the same as in mania.
Table 4. DSM-IV criteria for Hypomanic Episode
A.   A distinct period of persistently elevated, expansive, or irritable mood, lasting throughout at least
     4 days, that is clearly different from the usual nondepressed mood.
B.   During the period of mood disturbance, three (or more) of the following symptoms have persisted
     (four if the mood is only irritable) and have been present to a significant degree:
     1.  inflated self-esteem or grandiosity
     2.  decreased need for sleep (e.g., feels rested after only 3 hours of sleep)
     3.  more talkative than usual or pressure to keep talking
     4.  flight of ideas or subjective experience that thoughts are racing
     5.  distractibility (i.e., attention too easily drawn to unimportant or irrelevant external stimuli)
     6.  increase in goal-directed activity (either socially, at work or school, or sexually) or
         psychomotor agitation
     7.  excessive involvement in pleasurable activities that have a high potential for painful consequences
         (e.g., the person engages in unrestrained buying sprees, sexual indiscretions, or foolish business
         investments)
C.   The episode is associated with an unequivocal change in functioning that is uncharacteristic of
     the person when not symptomatic.
D.   The disturbance in mood and the change in functioning are observable by others.
E.   The episode is not severe enough to cause marked impairment in social or occupational functioning, or
     to necessitate hospitalization, and there are no psychotic features.
F.   The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse,
     a medication, or other treatment) or a general medical condition (e.g., hyperthyroidism).
NOTE: Hypomanic-like episodes that are clearly caused by somatic antidepressant treatment (e.g., medication,
     electroconvulsive therapy, light therapy) should not count toward a diagnosis of Bipolar II Disorder.
Diagnosis of bipolar disorder according to the Diagnostic and statistical manual of mental disorders,
Fourth Edition (DSM-IV), Text Revision (American Psychiatric Association, 2000)
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Some  criteria of mania and hypomania require  further consideration based on the literature
available. First, the definition of a hypomanic phase lasting at least 4 days in the
DSM-IV is arbitrary. Brief hypomania with 2 or more days is as widely accepted as valid as
the current definition of 4 or more days in the DSM-IV based on family history of BD,
symptom profile, and outcome (Coryell et al., 1995; Akiskal et al., 2000; Benazzi, 2001a;
Angst et al., 2003; Judd et al., 2003a). Second, the weakest point in the differential
diagnosis of hypomania and mania arises from the ill-defined qualifying words "without
marked social or occupational dysfunction", which must be interpreted by the classifier
without any further instructions. Given that currently manic patients tend not to have
insight into this aspect of the illness (Dell’Osso et al., 2002), and insight seems to be
poorer in BD II when the mood is stabilized (Pallanti et al., 1999), other informants are
often needed. Third, the distinction between normally and "abnormally" elevated mood is
often not clear.
Not all bipolar patients experience depressive phases. The prevalence of unipolar mania is
reported in only two studies. Angst et al. (Angst et al., 2004) describe that in a sample
of hospitalized patients, followed-up prospectively for a mean of 17.6 years (0-33 years),
14/160 BD I patients (8.8%) had only manic episodes. However, the diagnosis was not
confirmed in a structured interview, the follow-up time varied markedly, and only 43% of
patients were interviewed personally. Yazici et al. (Yazici et al., 2002) note that 48/272
patients (17.6%) with manic episodes from a mood disorder unit in Istanbul had no major
depressions in at least 4 years of retrospective follow-up. No study has reported the
prevalence in a representative sample of patients, but most likely in outpatient samples
with prospective follow-up, the prevalences would be considerably lower. The true
existence of unipolar mania is often questioned (Goodwin, 1990). However, two prospective
studies suggest at least some patients have a stabile form of unipolar mania (Shulman and
Tohen, 1994; Solomon et al., 2003). In one study of 50 BD patients who at baseline had had
at least 3 manic phases without depression, 6/50 (12%) stayed unipolar manic in a 5-year
follow-up (Shulman and Tohen, 1994). In another study, 7/27 unipolar manic patients (26%)
had no major depressions during 15-20 years of follow-up, and 5/27 patients (19%) did not
even have minor depressions (Solomon et al., 2003).
4.1.4 Mixed phase
The term mixed states was introduced and described by Kraepelin in 1896 (Angst and
Marneros, 2001). He distinguished two general classes of mixed states: a transition form,
where depression changes into mania or vice versa, and an autonomic form, a disorder of
its own (Angst and Marneros, 2001; Marneros, 2001b). He also distinguished six subtypes of
mixed states: three were based on manic mood (basic elements of euphoria, flight of ideas,
and hyperactivity), and three on depressive mood (basic elements of depressive mood,
depressive thoughts, and weakness of volition) (Marneros, 2001b). For instance, a
depressive or anxious mania is evident if euphoria is replaced by depressive mood, but two
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of the three basic elements of mania are present (Marneros, 2001b). Also, manic stupor is
present when mood is euphoric, but two other major components of depression are evident
(Marneros, 2001b). Basically, three modern definitions of mixed states can be presented:
1) broad definitions, where the presence of single depressive symptoms within a manic
phase is considered sufficient for a mixed phase, 2) narrow or strict definitions, where
only the co-existence of full symptomatology of a manic and depressive phase allows the
diagnosis of a mixed phase, and 3) moderate definitions, where prominent depressive
symptoms within a manic or hypomanic phase are sufficient (Marneros, 2001b).
In the DSM-IV, strict criteria are used: the criteria must be met for both a manic episode
and a major depressive episode (except for duration) nearly every day over at least a
1-week period (APA, 1994). Thus, the DSM-IV describes a mixed episode to be present only
in BD I, with no equivalent in BD II. In addition, either alternating or concurrent
symptoms of mania and depression are present (APA, 1994). A mixed episode thus defined has
been prevalent currently in 7-24% of hospitalized manic patients (Sato et al., 2002;
Gonzalez-Pinto et al., 2003; Berk et al., 2005) and in 3% of BD patients from a treatment
system (Bauer et al., 2005b). The nature of pure manic and mixed phases differs in terms
of phenomenological presentations (Dilsaver et al., 1999; Cassidy et al., 2000), natural
course (Cassidy and Carroll, 2001), and specific treatment responses (Swann et al., 1997).
Much more confusion in the literature exists in differentiating manic and mixed states
than manic and hypomanic states.
The differences in the severity of manic and depressive symptoms in a mixed phase or mixed
vs. manic phase remain controversial. In most studies, the manic symptoms seem
qualitatively and quantitively similar in manic and mixed states, and the difference stems
from the number of depressive symptoms (McElroy et al., 1995). Some report manic and
depressive symptoms to have a strong positive relationship (Bauer et al., 2005b).
Only a few studies have longitudinally analyzed the individual constancy of specific
features of manic and mixed phases such as psychotic symptoms in mania or presence of
mixed features. Existence of psychotic features in mania does not seem a stable feature:
in a 15-year follow-up, patients who had psychotic features at intake mania were only
twice as likely to have psychotic features in follow-up compared with patients with
nonpsychotic mania at intake (Coryell et al., 2001). Patients with a current mixed phase
are more likely to have had a mixed phase as a first episode than manic patients (McElroy
et al., 1995), and to longitudinally have a greater number of mixed phases (McElroy et
al., 1995). In an individual, mixed and manic states can alternate longitudinally without
full stability of the pattern (McElroy et al., 1995; Perugi et al., 1997; Sato et al.,
2003). The constancy of mixed or manic episodes during hospitalizations appeared more
constant than by chance alone in one register study, the number of constant cases still
being only 20% (Woods et al., 2001). The constancy was greater in a clinical study in
hospitalized manic (57/62, 92% of manic patients) than mixed (13/68, 69.2%) patients from
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the first to second phase (Cassidy et al., 2001a). Adolescents may have more mixed manias
and rapid or ultrarapid cycling than adults, but long-term studies are needed to confirm
whether this model is to be changed in adulthood for these patients or whether it is a
feature of early onset BD (Kyte et al., 2006).
The DSM-IV definition of a mixed state is problematic for four reasons: 1) the mixed
features are evident in a dimensional rather than a strictly categorical manner, 2) a
mixed state for BD II is not included, 3) simultaneous occurrence of manic and depressive
symptoms and ultrarapid cycling mood (change of depressive and manic mood faster than the
time periods required for a major depressive or manic phase) are not differentiated, and
4) some symptoms of mania and depression overlap (McElroy et al., 1995).
4.1.5 Depressive mixed phase
No official diagnostic system includes a mixed state for BD II. However, it seems that
sub-threshold admixtures of depression with hypomania are common (Angst and Marneros,
2001; Bauer et al., 2005b) as a milder form of mixed states, corresponding to the
differences between manic and hypomanic states. In Europe, the term depressive mixed
state, and in the US, mixed hypomania have been used. However, increasing evidence
supports the existence and significance of the prevalence of manic symptoms in depression
(in 70%) and depressive symptoms in hypomania/mania (Bauer et al., 2005b; Suppes et al.,
2005). In the Stanley Foundation Bipolar Treatment Network cohort, at 57% of visits with
hypomanic patients, the criteria of mixed hypomania were met (Suppes et al., 2005); mixed
hypomania was defined as a state when the Young Mania Rating Scale score was ≥12 and the
Inventory of Depressive Symptomatology – Clinician-Rated Version (IDS-C) ≥15 (Suppes et
al., 2005). Benazzi and Akiskal (Benazzi and Akiskal, 2001) have studied the prevalence of
depressive mixed states when defined to fulfill the criteria of a major depressive phase
with two or more (DMX2) or three or more (DMX3) simultaneous hypomanic symptoms. Thus
defined, the prevalence of DMX3 has been 46.3% in BD II patients and 7.8% in MDD patients,
and that of DMX2 73.1% in BD II patients and 42.1% in MDD patients (Benazzi and Akiskal,
2001; Berk et al., 2005). Furthermore, the prevalence of DMX2 in depressed bipolar
patients was 81.8% (Akiskal and Benazzi, 2003).
The stability of depressive mixed states needs to be validated longitudinally. In a
retrospective follow-up study (Sato et al., 2003), the presence of categorical depressive
mixed states was constant in 71% of bipolar patients, and the dimensional score of the
number of intra-episode manic symptoms was moderately significant; the authors interpreted
the results as indicating that the inter-episode stability of DMX was not sufficiently
high to establish a distinct clinical entity.
The broader the definition of mixed states, the more evident the need for phenomenological
exactness in differentiating between state and trait of patients. Obviously, the various
definitions and clinical picture of bipolar mixed states together form a spectrum that
extends from the occurrence of depressive features within mania to the occurrence of manic
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features within depression, with admixtures in between (McElroy et al., 1995; Berk et al.,
2005). Thus, a dimensional view of mood becomes necessary: depressive and manic symptoms
are dimensionally present to a varying extent even in the same individual. Some authors
hypothesize that a mixed state, rather than an independent state of mood, is evident when
an episode arises from a temperament of opposite polarity (Marneros, 2001b). Akiskal et
al. (Marneros, 2001b) have speculated that depressive temperament with manic psychosis,
cyclothymic temperament with depression, or hyperthymic temperament with depression
underlie a mixed symptomatology. While this has not been validated, the opposite was true
(Perugi et al., 1997). Furthermore, the authors do not use the term "temperament" as a
normal variant of healthy persons, but have constructed the criteria based on samples of
mood disorder patients; thus, the borders of subsyndromal states of mood are not
clear-cut. Thus far, the definition provided by Benazzi and Akiskal (Benazzi and Akiskal,
2001) DMX3 seems most suitable as a categorical state comparable to mixed states in BD I,
but the term needs to be validated and the results replicated by independent authors.
Careful evaluation of the demarcation between depressive mixed state and borderline
personality disorder is also needed (Magill, 2004).
4.1.6 Differences between depressive patients with bipolar or major
depressive disorder
Several clinical studies have tried to differentiate patients with unipolar and bipolar
depression [recently reviewed in (Bowden, 2001; Skeppar and Adolfsson, 2006)]. The
strongest evidence distinguishing BD patients from MDD patients comes from family risk
studies. BD patients have more often had a family history of BD (Angst, 1986; Cassano et
al., 1992; Winokur et al., 1993a; Winokur et al., 1993b; Ghaemi et al., 2004; Perlis et
al., 2006a). In addition, BD patients typically have an earlier age at illness onset
(Cassano et al., 1992; Winokur et al., 1993a; Hantouche et al., 1998; Benazzi, 2001b;
Kupfer et al., 2002; Serretti et al., 2002a; Akiskal and Benazzi, 2005; Perlis et al.,
2006a). BD I patients have the earliest age at illness onset (Cassano et al., 1989;
Serretti et al., 2002a; Berk and Dodd, 2005), at first treatment (Serretti et al., 2002a),
and at first hospitalization (Cassano et al., 1989).
In prospective studies, BD patients have had a higher total number of episodes (Winokur et
al., 1993a; Winokur et al., 1993b), depressive phases (Cassano et al., 1992; Ghaemi et
al., 2004; Akiskal and Benazzi, 2005; Perlis et al., 2006a), and hospitalizations (Winokur
et al., 1993b). BD I patients have had the greatest number of illness episodes (Serretti
et al., 2002a) and hospitalizations (Serretti et al., 2002a). In one study, BD I patients
had the most depressive phases (Cassano et al., 1989), but no statistically significant
difference was evident in another study (Serretti et al., 2002a). Postpartum depression is
common in BD (Goodwin, 1990; Ghaemi et al., 2004). BD patients are also more affected by
seasonality (Shin et al., 2005).
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Cross-sectional differences in depression of BD and MDD patients remain controversial. BD
patients have had more psychotic features in depression (Mitchell et al., 2001), with BD I
patients having the most (Serretti et al., 2002a). No differences in symptom scores
between BD I and MDD were detected in some studies (Hantouche et al., 1998; Benazzi, 1999;
Mitchell et al., 2001), while in a study with patients mixed from clinical and genetic
studies, MDD had more serious depressive symptoms than BD I (Serretti et al., 2002a), and
in a sample from three depression treatment studies, BD I had more serious depressive
symptoms than MDD (Perlis et al., 2006a).
Several studies [reviewed in (Berk and Dodd, 2005; Skeppar and Adolfsson, 2006)] suggest
that depression in BD (especially BD II) is characterized by such atypical features as
hypersomnia, hyperphagia, marked fatigue, and rejection sensitivity (APA, 1994). In recent
studies with BD and MDD patients, BD patients have had more atypical features of
depression (Benazzi and Rihmer, 2000; Benazzi and Akiskal, 2001; Mitchell et al., 2001;
Serretti et al., 2002a; Ghaemi et al., 2004). The DSM-IV criteria for melancholic
depression are loss of pleasure or mood nonreactivity, plus at least three of the
following criteria: distinct quality of mood from sadness, worse symptoms in the morning,
early morning awakening, marked psychomotor change, significantly decreased eating or
weight, and marked guilt (APA, 1994). The results from studies reporting differences in
the prevalence of melancholia in MDD vs. BD have been more controversial than from studies
on atypical depression; however, the prevalence of melancholia seems similar in different
mood disorders when overall severity of depression is controlled (Berk and Dodd, 2005),
although higher prevalence of melancholic features in BD I has also been suggested
(Skeppar and Adolfsson, 2006).
Temperamental features might form one etiologic factor underlying mood disorders (Akiskal
et al., 2000; Perugi and Akiskal, 2002; Skeppar and Adolfsson, 2006). The common
coexistence of personality disorders and mood disorders seems to support this theory.
Several studies have compared temperament behind mood disorders in BD and MDD patients,
as reviewed in (Mendlowicz et al., 2005), and BD I and BD II patients, as reviewed in (Savitz
and Ramesar, 2006), but thus far the results have been contradictiory and it remains
unclear which features are true etiological differences and which result from the
longitudinal course of the disorder. In other studies, some aspects of mood lability,
impulsivity, and aggression (excited depression, agitated depression, anger attacks,
irritation) have been found to be different between MDD and BD (Hantouche et al., 1998;
Serretti et al., 2002a; Maj et al., 2003; Benazzi et al., 2004; Deckersbach et al., 2004;
Perlis et al., 2004; Akiskal and Benazzi, 2005; Nowakowska et al., 2005; Serretti and
Olgiati, 2005). Recently, a dimensional spectrum of mood lability was suggested with
specific features differentiating BD, especially rapid and ultrarapid cycling, and
borderline personality disorder (MacKinnon, 2006). In a review of studies with BD I and II
patients, Savitz and Ramesar (Savitz and Ramesar, 2006) conclude that the results thus far
suggest that certain personality traits are associated with BD in a state-independent
manner, that personality is at least partly heritable, and that various temperaments
aggregate in the nonaffected relatives of bipolar probands. According to them, however, it
28
remains unclear whether specific personality traits co-segregate with affectively ill
individuals (Savitz and Ramesar, 2006). In many studies reporting temperamental features
in BD patients or comparing BD and MDD patients, the use of terminology is confusing, and
especially in studies describing features like agitation, limits of symptoms of mood
states, residual symptoms, and true temperamental (variants of normal) features are not
well defined.
Overall, clinical studies comparing depression in unipolar and bipolar patients have
several methodological limitations, most importantly that they seldom describe
representative patient samples of MDD, BD I, and BD II, but include only two of the
groups, and that they mostly comprise hospitalized patients. No study has been able to
describe a large set of characteristics in the same cohort, controlling for important
confounding factors like differences in symptom status. In addition, the magnitude of
differences mostly does not seem clinically relevant, and the results are largely
conflicting. Thus, the true differences in clinical characteristics and symptom profile
between unipolar and bipolar depression remain open and warrant further research.
4.1.7 Stability of diagnosis in mood disorders
Stability of diagnosis serves as one validator of MDD, BD I, and BD II, and thus,
incidences of conversion to another mood disorder, or switching, have been a subject of
research. Generally, a conversion is thought to only occur from MDD to BD I or BD II and
from BD II to BD I, while a later absence of manic or hypomanic phases is a sign of
recovery, not leading to a change in diagnosis. In the Iowa 500 study, patients that had
been hospitalized for a major depressive episode were followed for a mean of 4.3 years,
and 22/225 (9.8%) had a manic episode during this time (Winokur and Wesner, 1987). In a
mixed cohort of MDD patients (172 patients from an imipramine study, 53 hospitalized
patients, and 181 patients retrospectively assessed at intake), 50/209 (23.9%) were
bipolar after a median follow-up of 25 years (Angst and Preisig, 1995). In the NIMH
Collaborative Program on the Psychobiology of Depression – Clinical Studies, a study with
inpatients as well as outpatients, 19/381 (5.0%) had hypomania and 20/381 (5.2%) mania
during the 10-year follow-up (Coryell et al., 1995). Furthermore, 12/94 BD II patients
(12.8%) developed mania (Coryell et al., 1995). In a study of outpatients with an initial
diagnosis of MDD (mean age at intake 44.4 years), 41/206 (19.9%) developed mania during a
mean prospective follow-up of 3 years; the high proportion might be explained by 90% of
patients being in their first or second mood episode (Akiskal et al., 1983). In a sample
of 74 young patients (mean age at intake 23.0 years) hospitalized for depression, 30/74
(41%) had hypomania or mania during the 15-year follow-up (Goldberg et al., 2001). The
conversion from MDD to BD II might be as common (5.0% vs. 5.2%) (Coryell et al., 1995) or
slightly more common (27% vs. 19%) (Goldberg et al., 2001) than that from MDD to BD I. The
conversion from MDD to BD seems highest during the first 5 years of follow-up (Coryell et
al., 1995) or equally distributed (Goldberg et al., 2001). In studies of depressed
adolescents, 20-49% became bipolar in 7-15 years of follow-up (Geller et al., 2001). In
summary, then, polarity conversion from MDD to BD is estimated to be 1-2% per year
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(Winokur and Wesner, 1987; Angst and Preisig, 1995; Coryell et al., 1995), and conversion
from BD II to I from less than 1% to 2% per year in a longer follow-up (Coryell et al.,
1995; Angst et al., 2005). The switch rate from BD to schizoaffective disorder or
schizophrenia in a follow-up study of patients hospitalized for first mania was 7/173
(4.0%) (Tohen et al., 2003).
Reported predictors of switching from MDD to BD [reviewed in (Goldberg et al., 2001)]
include younger age at intake (Akiskal et al., 1983; Winokur and Wesner, 1987), earlier
age at onset (Akiskal et al., 1983; Angst and Preisig, 1995), bipolar family history
(Akiskal et al., 1983; Angst and Preisig, 1995; Goldberg et al., 2001), higher number of
episodes (Angst and Preisig, 1995), atypical, hypersomnic, or retarded features of
depression (Akiskal et al., 1983), pharmacological hypomania (Akiskal et al., 1983),
postpartum episodes (Akiskal et al., 1983), psychotic depression (Akiskal et al., 1983;
Goldberg et al., 2001), more hospitalizations (Winokur and Wesner, 1987), and hypomanic
symptoms (Regeer et al., 2006). In a 15-year follow-up study, a switch from MDD to BD was
prevalent in 9% of patients without psychotic features, but in 20% of patients who met
DSM-IV criteria for depressive disorders with psychotic features (Jager et al., 2005). In
the NEMESIS study, the lifetime prevalence of hypomanic symptoms as measured by items of
CIDI in people without a diagnosis of BD was 1.2%, and in the 2-year follow-up the
positive predictive value of hypomanic symptoms for post-baseline depression was 17.9%,
and for post-baseline BD 7.1% (Regeer et al., 2006). Thus, the cross-prediction across
mood symptoms was high. In addition, the predictive value increased in a dose-response
fashion with increasing number of mood symptoms (Regeer et al., 2006).
Predictors of a switch from MDD to BD I include psychotic features (Akiskal et al., 1995;
Coryell et al., 1995; Jager et al., 2005), greater severity of intake episode (Akiskal et
al., 1995), and a family history of mania or schizoaffective mania (Coryell et al., 1995).
Predictors of switching from MDD to BD II include younger age at intake (Akiskal et al.,
1995; Coryell et al., 1995), mood instability (Akiskal et al., 1995), and duration of
depression of more than 2 years (Coryell et al., 1995). Predictors of a switch from BD II
to I remain open; one study found no differences between the 12 switchers and 59
nonswitchers (Coryell et al., 1995), but the power of the study was poor.
Most bipolar patients could be said to be "switchers" given that several studies uniformly
report that 60% of BD begins with a depressive phase (Lish et al., 1994; Tondo et al.,
1998; Judd et al., 2003b; Morselli and Elgie, 2003). Delay from the first depression to
the first mania was in one study a mean of 6.4 years (median 4 years) (Akiskal et al.,
1983). However, this means that the younger the cohort of mood disorder patients, the more
likely they are to convert in follow-up. Thus, a study reporting the relation of patients’
age at intake, age at onset, age at conversion, and time in follow-up is needed. Some of
the patients might not be true converters, but false switchers arising from diagnostic
problems. The diagnostic criteria have changed since the beginning of the follow-up, and
none of the studies was initiated using the current DSM-IV criteria of BD II; thus, some
BD II might have been diagnosed as MDD at intake. Several factors may therefore explain a
30
portion of the converters. In any case, the proportions can be said to be moderate, and
diagnostic stability is commonly used as a validator of the three mood disorders (MDD, BD
I, and BD II). Since switching is relatively uncommon, it is difficult to have cohorts
with the power to detect predictors of conversion after a long follow-up.
4.1.8 Alternative views of mood disorders
Whereas abundant evidence exists on the differences between MDD and BD to support their
categorical division into two disorders, the division of BD into types I and II has been
the subject of more controversy. At least five models of mood disorders have their
supporters: 1) the three-disorder model of MDD, BD I, and BD II as introduced in previous
sections, 2) a two-disorder model with MDD and BD, 3) the dimensional model of mood 
disorders, 4) a four-disorder model with separate MDD, BD I, BD II, and bipolar spectrum 
disorders, and 5) a two-disorder model with concurrent or alternating major depression and
mania, where the two are coexisting in some (currently bipolar) individuals like comorbid
disorders. The diagnostic boundaries of these categories do not necessarily follow the
boundaries of BD and MDD diagnoses as defined in the DSM-IV.
Criticism of the categorical distinction of MDD and BD as reviewed in (Cassano et al.,
2004) is based on: 1) clinical studies showing that BD is frequently misdiagnosed as
unipolar MDD and consequently mistreated (Manning et al., 1997; Hantouche et al., 1998;
Ghaemi et al., 1999; Ghaemi et al., 2001; ten Have et al., 2002; Kessing, 2005a; Kiejna et
al., 2006), and patients with recurrent unipolar major depression have a significant
number of manic or hypomanic symptoms (Cassano et al., 2004; Serretti and Olgiati, 2005);
thus, no clear-cut limit between the two disorders is found; 2) theoretical studies
warning about the limitations of the categorical diagnoses of BD and unipolar depression
(Kendler and Gardner, 1998; Benazzi and Akiskal, 2001; Akiskal and Benazzi, 2003; Kelsoe,
2003; Alda, 2004; Berk et al., 2005; MacQueen et al., 2005); 3) epidemiological studies
supporting a widening of the boundaries of the bipolar spectrum to include hypomania,
cyclothymia, and BD NOS (Angst, 1998); 4) familial and genetic studies indicating that the
familial aggregation of BD and severe unipolar depression is at least partly due to common
genetic factors and that the etiology of such broad syndromes as MDD and BD is
multifactorial (McGuffin and Katz, 1989; Duffy et al., 2000); and 5) lack of validity of
these diagnostic categories in terms of zones of rarity (Kendell and Jablensky, 2003).
The dimensional view of mood disorders above lies at the foundation of the so-called
spectrum models. The term "spectrum" was first used in psychiatry by Kety et al. (Angst
and Cassano, 2005) in a description of schizophrenia spectrum disorders and refers to the
broad range of disorder manifestations, from core symptoms to temperamental traits
(Cassano et al., 2002) . The manifestations of the spectrum may represent during, between,
or in the absence of a full-syndrome level of the disorder. It has been proposed that all
forms of BD and perhaps all primary mood disorders are best conceptualized as a spectrum
of related illnesses that overlap clinically and are genetically heterogeneous (Judd et
al., 1997; Kendler and Gardner, 1998; Judd and Akiskal, 2000; Judd et al., 2003b; Kelsoe,
2003; Alda, 2004; MacQueen et al., 2005).
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The bipolar spectrum (Angst and Cassano, 2005) describes a continuum of symptoms
comprising a complex range of bipolar subtypes (Perugi and Akiskal, 2002; Angst and
Cassano, 2005). However, use of the term is extremely confusing. A framework for
dimensions used in the definition of bipolar spectrum as suggested by Goodwin (Goodwin,
1990) includes 1) severity of depressive, manic, and mixed states, 2) polarity, 3)
cyclicity, 4) duration of episodes, 5) instability or rapidity of state changes, and 6)
responsivity to treatment. Some speak of bipolar spectrum comprising only BD I and II,
while others expand it to include up to half of mood disorder patients (Angst and Cassano,
2005). Klerman in 1981 suggested a continuum of manic conditions to include 1) mania, 2)
hypomania, 3) hypomania or mania induced by drugs, 4) cyclothymic personality, 5)
depression with family history of mania, and 6) mania without history of depression (Angst
and Marneros, 2001). Based on the severity of symptoms, Angst has distinguished between
hypomania (m), cyclothymia (md), mania (M), mania with mild depression (Md), mania and
major depression (MD), and major depression with hypomania (Dm) (Angst and Cassano, 2005).
Soft bipolar spectrum is a term coined by Akiskal (Perugi and Akiskal, 2002; Akiskal et
al., 2006) This spectrum is characterized by a recurrent tendency to hypomanic excursions
which, when coupled with depressive periods of varying duration and severity, give rise to
the various subtypes of the spectrum (Akiskal et al., 2006). The soft bipolar spectrum
disorders are characterized by personality-like features, are built on several temperament
types, are constant, and rarely lead to hospitalization or other serious outbursts (Perugi
and Akiskal, 2002). Recently, in genetic studies, the bipolar spectrum has been used to
refer to psychopathological states or endophenotypes that may share a common genetic basis
(Kelsoe, 2003; Alda, 2004; MacQueen et al., 2005). To conclude, no consensus has yet been
reached on the term bipolar spectrum, and this is reflected in the results of spectrum
research not being comparable.
Some researchers suggest a comorbidity of depression and mania as distinct disorders
rather than as a single bipolar disorder (Joffe et al., 1999; Schweitzer et al., 2005).
The authors state that if mania and depression are opposite poles of a unitary disease
entity, both should respond to the same treatment, which according to them is not the
case. However, several authors have argued against the comorbidity theory using the same
study results against the model as Joffe et al. used to support the model and state that
at least lithium is a drug of choice for both mania and depression (Dunner, 1999; Swann,
1999).
The dimensional view of mood disorders is mainly criticized for the poor clinical utility
of the concept (Patten, 2006). Dimensions are more difficult to integrate, for example,
with clinical practice guidelines. Dimensional symptom ratings can hardly guide treatment;
for instance, a high depressive score can be due to normal bereavement (Patten, 2006). A
spectrum that does not clearly differentiate temperament and personality, or overt
psychopathology, may not be useful in clinical practice (Patten, 2006). One important
measure of clinical utility would be any evidence that spectrum disorders benefit from
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treatment (Patten, 2006). For the purposes of research, defining a spectrum disorder too
broadly and unspecificly may dilute results in studies searching for underlying etiology
(Patten, 2006).
Although this argumentation between categorical and dimensional view only a few years ago
seemed to be "either-or" directed, a consensus is now being formulated similar to that of
comorbidities, that is, both views are needed for different clinical and research
purposes. Discrete, categorical disease entities and dimensions of continuous variation
are not mutually exclusive means of conceptualizing psychiatric disorders; both are
compatible with a threshold model of disease and may account for different or even
overlapping psychiatric morbidity (Kendell and Jablensky, 2003). The difference between
categorical and dimensional views is diluted because dimensionally measured features can
be divided categorically, categories can be used as dimensions, and many categorical
disorders include dimensionally defined criteria. In clinical practice and for purposes of
research of treatment, categorical diagnoses might be the only practical way to classify
the disorders, but in etiological and epidemiological studies, dimensional views can add
important information. The reliable characterization and validation of sub-syndromal
states similar to BD would enhance research on genetic markers and modes of genetic
transmission, provide an approach for identifying individuals at increased risk for
development of BD, and permit the evaluation of early intervention treatments (Goodwin,
1990). After conducting long follow-up studies on both MDD and BD, Judd et al. (Judd et
al., 2003b) recently recommended a combination of categorical and dimensional views of BD,
stating:
    The number of significant differences between BP (bipolar disorder) I and BP II presents an
    argument to support the conceptualization of these two disorders as being different illnesses.
    At the same time, there are a sufficient number of qualitative similarities between BP I and
    BP II to suggest that they exist in a clinical spectrum... BP I and BP II may thereby
    represent, respectively, manic and depressive extremes in an affective liability threshold
    model.
4.2 Comorbidity of bipolar disorder and major depressive disorder
Unipolar and bipolar mood disorders are highly comorbid (Szadoczky et al., 1998; de Graaf
et al., 2003). This co-occurrence of mental syndromes is important for both theoretical
and clinical reasons. In investigating possible etiological and phenomenological
continuities and differences between MDD and BD, information on patterns of comorbid
disorders and the possible dependence of these patterns on illness episodes, phases,
subtypes, or other factors, such as gender, is required. From a clinical perspective,
presence of comorbidity has a profound impact on course, prognosis, outcome, and quality
of episodes of mood disorders (Kessler et al., 1999; Pini et al., 1999; Dunayevich et al.,
2000; McElroy et al., 2001; Dittmann et al., 2002; Boylan et al., 2004; Simon et al.,
2004b; Gaudiano and Miller, 2005; Strakowski et al., 2005), increasing healthcare
utilization (Cassidy et al., 2001b) and complicating treatment (Colom et al., 2000;
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McIntyre et al., 2004; Simon et al., 2004a; Gaudiano and Miller, 2005; Singh and Zarate
Jr, 2006). To date, the psychiatric comorbidity of unipolar MDD has been more extensively
investigated, whereas the picture of differences in the overall pattern of comorbidity
between bipolar I and II disorders and unipolar and bipolar disorders appears more
fragmentary.
4.2.1 Definition of the concept
Comorbidity refers to the co-occurrence of two or more distinct disorders in one person
over a defined period of time. The concept has been used in general medicine and applied
to psychiatry initially for research purposes, especially since the construction of
DSM-III (APA, 1980). The categorical approach to diagnosis used in the DSM assumes that
one disorder is present or absent according to the presence or absence of specified
criteria, thus allowing for several distinct disorders to be present at the same time. A
dimensional view of comorbidities is widely used, particularly in describing personality.
Three main alternative theoretical models of psychiatric comorbidity have been presented:
1) the co-occurrence of multiple disorders is better reformulated as complexity of many
psychiatric conditions, and co-occurrence of discrete diseases as an artifact of the
existing diagnostic systems, 2) although psychopathology consists of discrete entities,
current diagnostic categories do not fully reflect these entities and require
simplification, further elucidation, or both in various areas of comorbidity; and 3) the
nature of heterogeneity is intrinsic, consisting partly of true disease entities and
partly of maladaptive response patterns such as anxiety (Maj, 2005).
4.2.2 Current comorbidity of bipolar disorder
In clinical studies reporting current comorbidity of BD I and II (Table 5), total axis I
comorbidity has been estimated to be 40% (McElroy et al., 2001), anxiety disorders 30%
(McElroy et al., 2001; Simon et al., 2004a), and substance use disorders 4-13% (McElroy et
al., 2001; Simon et al., 2004a) or as high as 42% (Strakowski and DelBello, 2000). Only
some areas of comorbidity have been investigated in BD [recently reviewed in (McIntyre et
al., 2004; Bauer et al., 2005a; Krishnan, 2005)], because no study has reported all
structurally assessed axis I and II disorders, most studies have been conducted using
DSM-III-R criteria, bipolar II has almost always been underrepresented, and estimates of
prevalence of comorbid disorders in psychiatric settings may be skewed due to poor
recognition of BD.
Few studies (McElroy et al., 2001; Bauer et al., 2005a) describe the overall pattern of
current axis I comorbidity, although current prevalences correspond to the clinical
situation better than lifetime prevalences. This is probably because psychiatric
comorbidity should be evaluated only in euthymic patients. However, it is theoretically
relevant to determine the extent to which the current phase affects prevalences of
comorbidity and how constant comorbid disorders remain in follow-up. Only fragmentary
information from highly selected populations with BD is available. One study that
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evaluated cross-sectionally the presence of two current axis I disorders in manic and
mixed patients (Dilsaver and Chen, 2003) reported lower prevalences in manic patients,
which is supported by lower lifetime axis I prevalences in manic patients in another study
(Dell’Osso et al., 2000). Lifetime prevalences of comorbidity in psychotic patients were
highest in depressive BD I patients and lowest in manic patients in one study (McElroy et
al., 1995); in another study, no differences in lifetime comobidity of distinct anxiety
disorders were found (Dell’Osso et al., 2000). Thus, it remains controversial whether and,
if so, by how much current illness phase affects prevalences of axis I disorders in BD.
Axis II diagnoses may also be inflated by the presence of a current mood episode (Peselow
et al., 1995).
4.2.3 Comorbidity of bipolar disorder during lifetime
Several clinical studies have reported lifetime prevalences of comorbid DSM-IV axis I
disorders in BD (McElroy et al., 2001; Suppes et al., 2001; Dittmann et al., 2002; Henry
et al., 2003; Judd et al., 2003b; Simon et al., 2004a; Bauer et al., 2005a), but
information is more conflicting than on current prevalences. Total axis I lifetime
comorbidity in bipolar patients has been estimated at about 60-80% (Pini et al., 1999;
McElroy et al., 2001; Suppes et al., 2001; Simon et al., 2004a; Bauer et al., 2005a) or as
low as 35% (Vieta et al., 2000; Vieta et al., 2001; Dittmann et al., 2002). More
specifically, estimates of lifetime prevalence of comorbid anxiety disorders vary between
42% and 56% (McElroy et al., 2001; Henry et al., 2003; Boylan et al., 2004; Simon et al.,
2004a; Bauer et al., 2005a). The reported lifetime prevalences of substance use disorders
in BD are higher in recent American studies (33-72%) (Kay et al., 1999; Cassidy et al.,
2001b; McElroy et al., 2001; Suppes et al., 2001; Judd et al., 2003b; Simon et al., 2004a;
Bauer et al., 2005a) than in European studies (15-26%) (Pini et al., 1999; Vieta et al.,
2000; Vieta et al., 2001; Dittmann et al., 2002) [for review including older studies, see
(Cassidy et al., 2001b; Bauer et al., 2005a)].
The prevalence of personality disorders appears higher in studies focusing only on axis II
disorders (30-50%) (Peselow et al., 1995; Ucok et al., 1998; Kay et al., 1999; Brieger et
al., 2003; George et al., 2003) than in studies also including axis I disorders (25-33%)
(Colom et al., 2000; Vieta et al., 2000; Vieta et al., 2001). The prevalence of axis II
diagnoses may also be inflated by the presence of a current mood episode (Peselow et al.,
1995); a more accurate view would likely be achieved by using additional informants
(Peselow et al., 1995). However, the presence of a personality disorder may also influence
the likelihood of a mood episode.
No differences between bipolar I and II have been found in total axis I (McElroy et al.,
2001; Suppes et al., 2001; Dittmann et al., 2002) and substance use disorders (McElroy et
al., 2001; Suppes et al., 2001; Dittmann et al., 2002; Judd et al., 2003b), but anxiety
disorders are reported to be either equally distributed (McElroy et al., 2001; Suppes et
al., 2001; Dittmann et al., 2002) or up to twofold in BD II (Henry et al., 2003; Judd et
al., 2003b) (Table 5).
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Table 5. Differences in comorbidity of BD I and II patients
Comorbidity during lifetime         BD I>BD II        BD II>BD I        No statistical difference BD I vs. BD II
Axis I disorders                                         67% vs. 57% (McElroy et al., 2001)
                                                                    35.9% of 108 vs. 37.8% of 38 (Dittmann et al., 2002)
                                                                    146/214 (68%) vs. 30/47 (64%) (Suppes et al., 2001)
Any anxiety disorders                               27/71 (38%)     100/239 (42%) vs. 22/49 (45%) (McElroy et al., 2001)
                                                    vs. 32/135      92/214 (43%) vs. 23/47 (49%) (Suppes et al., 2001)
                                                    (23.7%)         10.4% of 108 vs. 18.4% of 38 (Dittmann et al., 2002)
                                                    (Judd et al.,   190/360 (5.8%) vs. 53/115 (46.1%) (Simon et al., 2004b)
                                                    2003b)
Any substance use disorders                                         107/239 (45%) vs. 15/49 (31%) (McElroy et al., 2001)
                                                                    90/214 (42%) vs. 16/47 (34%) (Suppes et al., 2001)
                                                                    25.5% of 108 vs. 28.9% of 38 (Dittmann et al., 2002)
                                                                    67/135 (49.6%) vs. 28/71 (39.4%)   (Judd et al., 2003b)
Any eating disorders                                                11/239 (5%) vs. 6/49 (12%) (McElroy et al., 2001)
                                                                    9.4% of 108 vs. 0% of 38 (Dittmann et al., 2002)
                                                                    30/214 (14%) vs. 10/47 (21%) (Suppes et al., 2001)
Comorbidity at intake
Axis I disorders                                                    84/239 (35%) vs. 28/49 (24%) (McElroy et al., 2001)
Any anxiety disorders               123/360 (34.2%)                 76/239 (32%) vs. 10/49 (20%) (McElroy et al., 2001)
                                    vs.
                                    22/115 (19.1%)
                                    (Simon et al.,
                                    2004b)
Any substance use disorders                                         9/239 (4%) vs. 3/49 (6%) (McElroy et al., 2001)
Any eating disorders                                                3/239 (1%) vs. 1/49 (2%) (McElroy et al., 2001)
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4.2.4 Comorbidity of bipolar disorder compared with major depressive
disorder
Some  epidemiological studies  have assessed  differences in comorbidity between MDD and
BD. The study with the largest number of bipolar subjects (Szadoczky et al., 1998) reported
those with MDD to have more comorbid axis I and total anxiety disorders than those with
BD, in contrast to other epidemiological findings (Kessler et al., 1997; Angst, 1998; de
Graaf et al., 2003). In these studies, substance use disorders were more prevalent, up to
60%, in BD (Angst, 1998; de Graaf et al., 2003). In the epidemiological studies where
differences in only a single comorbid disorder were reported, BD patients had twice as
much panic disorder (Chen and Dilsaver, 1995b), obsessive-compulsive disorder (OCD) (Chen
and Dilsaver, 1995a), social phobia (Kessler et al., 1999), and substance use disorders
(Regier et al., 1990; Winokur et al., 1998) as MDD patients. However, no clinical study
has compared the overall comorbidity profile of unipolar and bipolar mood disorders. Only
two clinical studies on anxiety disorders were available (Pini et al., 1997; Yerevanian et
al., 2001). Both studies described anxiety during lifetime to be more prevalent in MDD,
one reporting (comparing psychotic patients) 92% in MDD and 79% in BD (Pini et al., 1997),
the other (conducted retrospectively and based on patient charts) 48% in MDD, 48% in BD
II, and 12.5% in BD I (Yerevanian et al., 2001). One clinical cohort reported similar
prevalence of substance abuse disorders in BD and MDD (12% vs. 15%, ns) (Winokur et al.,
1998). One genetic study with a mixed sample of acute and euthymic patients reported
several distinct anxiety disorders to be more prevalent in BD (Simon et al., 2003).
On axis II, overall prevalence of personality disorders seems similar, but MDD patients
may have more cluster C and BD patients more cluster B personality disorders (Brieger et
al., 2003; Schiavone et al., 2004). The overall picture of MDD-BD differences is
conflicting and fragmentary due to variation in diagnostic, inclusion, and exclusion
criteria, treatment settings, and time periods investigated, and because focusing on
single comorbid disorders may result in inflated estimates of prevalence (Melartin et al.,
2002). Thus, the existence and quality of differences in the overall comorbidity of mood
disorders remain uncertain.
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4.3 Course and outcome of bipolar disorder
BD is a recurrent and chronic illness. Even though the natural course of some patients
includes full recovery after distinct phases, according to the latest clinical studies,
patients spend half of their time in a symptomatic state (Judd et al., 2003b; Judd et al.,
2003c; Post et al., 2003; Joffe et al., 2004), interepisode symptoms are extremely common
(Judd et al., 2003c), and practically all patients encounter affective recurrences
(Dittmann et al., 2002; Judd et al., 2003c; Perlis et al., 2006b). The disorder has a
profound influence on functional outcome, psychosocial factors, and quality of life, and
because of the burden of the illness on the individual, family, and society, it is among
one of the most disabling disorders worldwide (Morselli and Elgie, 2003).
4.3.1 Methods used to assess outcome in bipolar disorder
Several specific features of BD compared with MDD restrict the direct use of scores
developed for MDD when assessing BD outcome. Mixed episodes with concomitant depressive
and manic symptoms, rapidly changing mood and polyphasic episodes, and even improved
functionality in hypomanic phases are among these features. The need for uniform measures
of outcome in mood disorders is clear, and future research should aim to develop better
instruments for recognizing problems in the current terminology and methodology reported
in studies with MDD as well as with BD patients (Keller, 2003; Melartin, 2004). However,
in studies with both BD I and BD II, the diversity of methods is not as striking as in
studies on MDD.
The life chart methodology (LCM) is a generally accepted instrument of follow-up studies
of BD. In this method, the changes of mood are graphically presented, and other factors,
such as medication, hospitalizations, or life events, can be added in order to better
evaluate the causes and consequences of mood variation. The first life chart methodology,
the Longitudinal Interval Follow-Up Evaluation (LIFE), was developed for use in the
National Institute of Mental Health (NIMH) Collaborative Depression Study (CDS)
longitudinal reports (Judd et al., 2003b; Judd et al., 2003c) and has been slightly
modified with experience (Post et al., 1988). LIFE (or the NIMH life chart methodology,
NIMH-LCM) is used in all prospective clinical studies including BD types I and II
separately (Tondo et al., 1998; Dittmann et al., 2002; Judd et al., 2003b; Judd et al.,
2003c; Post et al., 2003; Joffe et al., 2004). However, despite seemingly using the same
life chart, rating has been done based on NIMH criteria of severity ratings (Tondo et al.,
1998; Dittmann et al., 2002; Judd et al., 2003b; Judd et al., 2003c; Post et al., 2003) or
cut-off scores in Young Mania Rating Scale (YMRS) and Hamilton Depression Scale
(HAM-D) in one cohort (Joffe et al., 2004). Moreover, the mood was classified in time
periods of whole weeks (Tondo et al., 1998; Judd et al., 2003b; Judd et al., 2003c), while
in one cohort (Post et al., 2003) exact durations in days was reported, and in other
studies, time units remain unclear (Tondo et al., 1998; Joffe et al., 2004); this
presumably affects the prevalence of phases, especially of shorter phases like hypomanias.
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4.3.2 Course specifiers
Some special course specifiers for BD are used. A chronically ill patient is defined as a
person who has been ill (in a monophasic or polyphasic episode) for the preceding two
years. In DSM-IV, rapid cycling has been defined as four or more distinct episodes
(phases) in one year (APA, 1994). Seasonal type means that during the previous two years
at least two major depressive phases and full remissions or shifts of mood were present at
the same time of year, no other depressions were evident, and seasonal depressions
dominate over nonseasonal depressions over the lifetime.
The most commonly used course specifier is rapid cycling [for review, see (Kupka et al.,
2003)]. In prospective follow-up studies, the prevalence of rapid cycling has been
15-38.2% (Maj et al., 1994; Baldessarini et al., 2000; Tondo et al., 2001; Coryell et al.,
2003; Schneck et al., 2004; Kupka et al., 2005). Of patients with rapid cycling at intake,
79.3% had a rapid cycling course during the next year, in contrast to 44.9% of nonrapid
cyclers (Post et al., 2003). Rapid cycling is more prevalent in women (Bauer et al., 1994;
Maj, 1999; Coryell et al., 2003; Schneck et al., 2004; Yildiz and Sachs, 2004; Kupka et
al., 2005). Patients prone to rapid cycling have younger age at onset in most (Coryell et
al., 2003; Schneck et al., 2004; Yildiz and Sachs, 2004), but not all (Bauer et al.,
1994), studies. Views of the constancy of rapid cycling vary: some see it as a transient,
nonfamilial manifestation of BD (Coryell et al., 2003), others suggest a familial form
(MacKinnon et al., 2002). A dimensional rather than a categorical definition of rapid
cycling has been supported because the number of phases is linearly distributed in all
available studies (Bauer et al., 1994; Kramlinger and Post, 1996; Maj, 1999; Kupka et al.,
2005).
A polyphasic episode, also known as switching of mood or "continuous cycling" in older
literature, is defined as a sequence of changing mood without remission in between (Maj et
al., 2002). This specifier is not included in the DSM-IV. Approximately half of patients
(47%) are estimated cross-sectionally to have a polyphasic episode (Coryell et al., 1987;
Winokur and Kadrmas, 1989; Maj et al., 2002). Correlates of a polyphasic episode include
family history of BD in one study (Winokur and Kadrmas, 1989) but not in another (Maj et
al., 2002), younger age at illness onset (Winokur and Kadrmas, 1989), and a depressive
index phase (Winokur and Kadrmas, 1989); no differences between polyphasic and monophasic
patients were found in gender (Maj et al., 2002) or age at first psychiatric contact (Maj
et al., 2002). Having polyphasic episodes is not a very constant feature: in a prospective
study of 165 BD I patients followed up for 7 years, 13% of the sample had only polyphasic
episodes, 33% only monophasic episodes, and 54% both types of episodes (Turvey et al.,
1999). In another study with a 10-year follow-up, patients who were monophasic at intake
retained the monophasic type in 62/73 cases (84.9%), while a polyphasic course was less
constant, in 56% of cases with initially poyphasic episodes (Maj et al., 2002).
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4.3.3 Course and outcome of bipolar patients
Several long-term outcome studies (Coryell et al., 1998; Maj et al., 1998; Judd et al.,
2002; Tohen et al., 2003; Goldberg and Harrow, 2004) show that BD I is a recurrent and
chronic disorder. BD has had a worse naturalistic course than MDD (Angst and Preisig,
1995; Goldberg and Harrow, 2004); one older study reported more episodes and
hospitalizations for BD, but a more chronic course for MDD (Winokur et al., 1993b).
Syndromal recovery is much more common than symptomatic and functional recovery in both
MDD (Keller, 2003) and BD I (Keck et al., 1998; Tohen et al., 2003; Goldberg and Harrow,
2004). Of 134 BD I patients hospitalized for a manic or mixed phase, syndromic recovery
occurred in 48%, symptoms continued in 26%, and functional recovery occurred in 24% over a
12-month period (Keck et al., 1998). Median time to full remission in 123 first-admission
psychotic BD I patients was 16 weeks, most relapses occurred within the first year after
remission, and the median time to recurrence was 22 months (Bromet et al., 2005). A large
multicenter study, STEP-BD, that included aggressively treated BD I and II patients but
reported the outcome for the whole cohort, stated that 858/1469 patients (58.4%) reached
full remission, and 416/858 patients (48.5%) subsequently experienced recurrences during
the two years of prospective follow-up (Perlis et al., 2006b). In a cohort of hospitalized
manic patients, 10/34 BD I patients (32%) had no full remission during the 10-year
follow-up (Goldberg and Harrow, 2004).
Several studies describe recent-onset BD I. In the Cincinnati study with 109 first-episode
patients, 50% of patients achieved syndromatic recovery, and 35% syndromic recovery within
one year (Strakowski et al., 1998). In the McLean-Harvard first-episode study, a cohort of
166 BD I inpatients was followed up for 2-4 years after the first lifetime hospitalization
for mania. Practically all patients (162/166; 97.6%) experienced syndromal recovery, but
28% remained symptomatic, only 43% achieved functional recovery, and 57% had new illness
episodes (Tohen et al., 2003). Syndromal recovery did not mean functional recovery;
subsyndromatic symptoms had an impact on functional capacity (Tohen et al., 2003).
However, these numbers might only reflect the good recovery found in manic and monophasic
episodes since no comparison group in a later phase of illness was used. In the Suffolk
County Mental Health Project, a 24-month follow-up of a subgroup of 155 first-admission
psychotic BD patients revealed that 74% achieved at least one 2-month period of full
remission, but only 41% reached functional remission (Global Assessment of Functioning
(GAF) Scale score >70) (Craig et al., 2004). In the NIMH study, 20 patients with a first
episode or multiple episodes of BD matched for gender and age showed no differences in the
number of episodes per year during the first 2 years (Winokur et al., 1993b). Thus, even
in first-episode patients, BD is a severe illness.
BD II patients seem to have a high number of depressive phases and spend half of their
time in depressive states in the few prospective studies describing BD II outcome (Coryell
et al., 1989; Judd et al., 2003a; Joyce et al., 2004).
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4.3.4 Differences between bipolar disorder types I and II in outcome
Only five prospective cohorts report information on outcome of BD I and II patients
separately (Coryell et al., 2003; Judd et al., 2003b; Judd et al., 2003c; Post et al.,
2003; Joffe et al., 2004; Kupka et al., 2005) (Table 6). The National Institute of Mental 
Health (NIMH) Collaborative Depression Study (CDS) included 146 RDC BD I (Judd et al.,
2002) and 86 BD II (Judd et al., 2003a) patients followed up for a median of 16 (2-12)
years. The patients spent half of the time syndromatically ill (Judd et al., 2003b).
Statistically significant differences in outcome between BD I and II were 1) the duration
of the index episode after intake of BD II being two times that of BD I, 2) BD II patients
more often having at least one new depressive phase and a higher number of depressive
phases, 3) BD II patients spending three times longer in phases of major depression and
depressive symptoms, and 4) BD I patients having more hospitalizations, mixed phases, and
time in hypomanic symptoms (Judd et al., 2002; Judd et al., 2003a; Judd et al., 2003c).
The percentage of weeks with subsyndromal affective symptoms, number of affective
episodes, and duration of episodes were similar in both groups (Judd et al., 2002; Judd et
al., 2003a; Judd et al., 2003b; Judd et al., 2003c). Thus, these recent findings from the
CDS suggest that BD II is an even more chronic disorder than BD I and is characterized by
a depressive course (Coryell et al., 1989; Judd et al., 2003b; Judd et al., 2003c; Judd et
al., 2005). However, the more depressive course of BD II was not evident in two other
studies describing differences between BD I and II, the Stanley Foundation Study (Post et
al., 2003) and a clinical study by Joffe et al. (Joffe et al., 2004).
The difference in the prevalence of rapid cycling course according to type of BD remains
unclear. Rapid cycling has been more prevalent in BD II than in BD I in some studies
(Bauer et al., 1994; Tondo et al., 1998; Maj, 1999; Maj et al., 1999; Coryell et al.,
2003; Koukopoulos et al., 2003), but more prevalent in BD I than in BD II in others
(Serretti et al., 2002b; Kupka et al., 2005), while still others report equal distribution
(Suppes et al., 2001; Dittmann et al., 2002; Schneck et al., 2004). The
controversial results might arise from differences in cohort sampling and definitions
of phases. BD I and II seem to have similar proportions of polyphasic index episodes
(Coryell et al., 1987; Maj et al., 2002).
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Table 6. Differences in outcome of BD I and BD II patients in prospective follow-up studies 1
                                    BD I>BD II        BD II>BD I        No statistical difference BD I vs. BD II
Number of phases, mean±SD (median)                                  3.3±2.5 (2.5) vs. 4.2±2.6 (4) (Judd et al., 2003b)
Number of depressive phases,                        2.5±2.4 (0) vs.
mean±SD (median)                                    0.8±1.1 (2)
                                                    (Judd et al.,
                                                    2003b)
Number of manic phases,             0.6±1.0 (0)
mean±SD (median)                    (Judd et al.,
                                    2003b)
Number of hypomanic phases,         0.5±0.8 (0) vs.
mean±SD (median)                    0.2±0.5 (0)
                                    (Judd et al.,
                                    2003b)
Duration of depression                                              median 12 weeks vs. 13 weeks (Judd et al., 2003b)
                                                                    mean 5.12±4.62 months vs. 4.51±3.36 months
                                                                    (Tondo et al., 1998)
Duration of mania                                                   median 6 weeks (Judd et al., 2003b)
Duration of hypomania                                               median 2 weeks vs. 6 weeks (Judd et al., 2003b)
Duration of hypomania or mania                                      mean 3.31±2.01 months vs. 2.86±2.50 months
                                                                    (Tondo et al., 1998)
Duration of all episodes                                            median 10 weeks vs. 13 weeks (Judd et al., 2003b)
                                                                    mean 4.06±2.68 months vs. 3.79±2.10 months
                                                                    (Tondo et al., 1998)
At least one new depressive phase                   34/46 (73.9%) vs .
                                                    41/82 (50.0%)
                                                    (Judd et al.,
                                                    2003b)
Recurrence                           Not specified                  0.74±0.86% vs. 0.72±1.34% (Tondo et al., 1998)
                                     (Dittmann
                                     et al., 2002)
Proportion of time in any mood                                      26.5±27.6 (16.2[0.0-100.0])% vs.
episode mean±SD (median[range])                                     32.7±27.9 (24.0[0.0-100.0])% (Judd et al., 2003b)
                                                                    19.56±18.44% vs. 16.09±21.47% (Tondo et al., 1998)
Proportion of time in major                         5.8±13.2        32.8% vs. 33.5% (Post et al., 2003)
depressive phase                                    (0.1[0.0-66.3])% Not specified (Joffe et al., 2004)
mean±SD (median[range])                             vs. 17.4±22.0
                                                    (9.4[0.0-84.6])%
                                                    (Judd et al.,
                                                    2003b)
Proportion of time in manic plus     7.2%                           11.8% vs. 7.6% (Post et al., 2003)
hypomanic phases, mean               vs. 1.0%
                                     (Judd et al.,
                                     2003c)
                                     2.0%
                                     vs. 0.4%
                                     (Joffe et al.,
                                     2004)
Proportion of time in depressive                    8.8±14.2
symptoms, mean±SD (median[range])                   (3[0-82])% vs.
                                                    14.2±16.4
                                                    (8[0-77])%
                                                    (Judd et al.,
                                                    2003c)
Proportion of time asymptomatic                                     53.4±34.1 (62[0-99])% vs. 44.2±33.1(43[0-100])%
(no depression or mania/hypomania),                                 (Judd et al., 2003c)
mean±SD (median[range])                                             Not specified (Joffe et al., 2004; Post et al., 2003)
1    Judd et al. report findings after the end of intake episode, others during the entire time in follow-up
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4.4 Epidemiology of bipolar disorder
4.4.1 Prevalence of bipolar disorder and bipolar spectrum
The  lifetime  prevalence  of BD I  is  commonly  estimated  to  be  about 1%, but  in  recent
epidemiological studies it has varied from 0.2% to 3.3% (Weissman et al., 1988; Kessler et
al., 1994; Bebbington and Ramana, 1995; Angst, 1998; Bijl et al., 1998; ten Have et al.,
2002; Grant et al., 2005; Kessler et al., 2005; Pini et al., 2005; Schaffer et al., 2006;
Perälä, 2007). The 12-month prevalence of BD is reported to be 0.1-2.0% (ten Have et
al., 2002; Mitchell et al., 2004; Kessler et al., 2005; Pini et al., 2005). In European
studies, a median of 0.9% was calculated (Pini et al., 2005). A rare disorder like BD is
difficult to find reliably in population studies, and the results have been highly
dependent on the diagnostic instrument (Kessler et al., 1997; Regeer et al., 2004; Angst,
2006; Perälä, 2007). Use of systematic diagnostic tools, such as the Diagnostic Interview
Schedule (DIS) and the Composite International Diagnostic Interview (CIDI), has increased
reliability (Bebbington and Ramana, 1995; Kessler et al., 2006), but in a study comparing
different screens to detect BD I, many cases still went undetected in population studies
(Perälä, 2007). No epidemiologic study has been able to use clinicians as primary
diagnosticians; at best, psychologists (Angst, 1998) (prevalence rate of bipolar spectrum
over a maximum period of 35 years 5.5%) or professional interviewers (lifetime prevalence
of BD I 3.3%) (Grant et al., 2005) were used; thus, prevalences appear to be lower with
lay interviewers.
BD I is only infrequently detected in epidemiological studies, but BD II is even more
difficult to establish with certainty (Bebbington and Ramana, 1995). With structured
interviews conducted by experienced psychiatrists, the diagnostic reliability of BD II can
be equal to BD I (Simpson et al., 2002); as noted above, this is not the case in
epidemiological studies. Only two studies on adults have given lifetime prevalences
separating BD I and II (Szadoczky et al., 1998; Scully et al., 2004), the former found the
lifetime prevalence of BD II to be higher (2.0%) than of BD I (1.5%) (Szadoczky et al.,
1998), the latter reported the opposite finding (BD II 0.1%, BD I 0.3%) (Scully et al.,
2004). The prevalence of hypomania in the Epidemiological Catchment Area Study (ECA)
database was 0.5%, lower than the 0.8% for mania (Weissman et al., 1988). Even when the
proportion of BD II in psychiatric care is known to be at least equal to that of BD I,
epidemiological studies seem to find only a small proportion of BD II.
The lifetime prevalence of bipolar spectrum (including mania, hypomania, and soft bipolar
spectrum) is estimated to exceed 6% (Angst, 1998; Szadoczky et al., 1998; Judd and
Akiskal, 2003; Moreno and Andrade, 2005; Pini et al., 2005; Kessler et al., 2006). In the
Zurich study, the DSM-IV criteria of hypomania were modified to be less strict in terms of
duration and severity (Angst and Cassano, 2005), and two alternative models were created.
The MDD to BD ratio with DSM-IV criteria was 9.4. While the more strict modified criteria
yielded a mood disorder prevalence of 49.5% and an MDD to BD ratio of 2.9, the less strict
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criteria gave the same prevalence of mood disorders, but a ratio of 1.0 for MDD to BD
(Angst and Cassano, 2005). However, the Zurich study cannot be seen as an epidemiological
study, and the prevalences seem highly overestimated. The same is true in the EPIDEP
study, where the rate of soft bipolar spectrum and MDD was reported to be 3:2 in patients
with a major depressive episode in psychiatric care (Akiskal et al., 2006). When the
limits are expanded, the prevalences clearly increase, but the broad definitions and the
high prevalences of bipolarity can be strongly criticized and their meaningfulness
questioned (Patten, 2006).
In Finnish studies, the prevalence of BD has been estimated to be lower than international
prevalences (Lehtinen et al., 1990; Veijola et al., 1996; Räsänen et al., 1998; Kieseppä
et al., 2004; Perälä, 2007). The most recent Finnish general population study, Psychoses
in Finland (PIF) (Perälä, 2007), used several screening methods and structured interviews
by psychiatrists to confirm the diagnosis of patients screening positive for psychotic
symptoms. The study reported a lifetime prevalence of 0.24% for BD I; with the inclusion
of register diagnoses of BD I the prevalence reached 0.42% (Perälä, 2007). The Tampere
Depression Project used the Present State Examination as a diagnostic instrument to
evaluate the prevalence of BD and MDD in primary care (N=437) and secondary care (N=435).
In community health centers, the 12 month prevalence of BD was 2.1%, and in community
mental health centers, 7.6% (Sorvaniemi and Salokangas, 2005). In Finland, the Hospital
Discharge Register includes the primary and secondary diagnoses of all psychiatric
patients who are hospitalized. Previously, the annual rate of BD in all hospitalized
patients was estimated at 0.03% (Räsänen et al., 1998). In another study, the annual
incidence of BD I was 5.8% (95% CI=5.4 to 6.3) (Kieseppä et al., 2004). The accuracy of
register diagnoses of BD I as compared with the SCID interview has been evaluated to be
good in a double-blinded study (Kieseppä et al., 2000); however, the accuracy was not
evaluated in patients given another diagnosis. Furthermore, comorbid diagnoses are seldom
indicated in the Hospital Discharge Register: in only 18% of hospital stays was any
comorbidity reported (Sorvaniemi and Hintikka, 2005). Moreover, the register study design
is highly vulnerable to undiagnosed BD. Rather than being due to late onset age (Räsänen
et al., 1998), the low prevalence and incidence of BD in Finland might indicate severe
underreporting of BD: first, not all BD I patients are hospitalized, and second, not all
are recognized as bipolar.
4.5 Recognition of bipolar disorder
The majority of BD patients are treated in psychiatric care (Kessler et al., 1997;
Morselli and Elgie, 2003), although 26% have never sought help for emotional problems (ten
Have et al., 2002). Even in psychiatric settings, BD is all too often incorrectly
diagnosed. Given the importance of understanding what leads to missing a diagnosis of
BD, surprisingly little information is available on this topic. Clinically, missing
(hypo)manic symptoms in anamnesis, lack of systematic evaluation, and some forms of
disorder can be suspected to lead to missed diagnosis. Misdiagnosed patients are thought
to usually be treated as unipolar depressive, borderline personality disorder, or
schizophrenic patients.
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                                                                       Time
                            First symptoms
Illness                     First major depressive phase
                            First mania/hypomania/mixed phase
Patient                     Contacting healthcare provider
Healthcare provider         Contacting psychiatric care
                            Diagnosis of BD
                            Starting medical and psychosocial
                            treatment
Figure 1. Time to adequate treatment of BD
           Patient-related                                        Healthcare provider-related
           Gender                                                 Resources
           Race                                                   Time available
           Insight                                                Diagnostic skills
           Stigma
           Family history
           Perceived need for treatment
           Experienced burden
           Temperament
           Personality
           Illness-related
           Type I or II BD
           Age at onset
           Mood incongruent psychotic features
           Dysphoric mania
           Severity
           Illness history
Figure 2. Factors behind unrecognized bipolar disorder
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4.5.1 Delay in diagnosis
Correct diagnosis is the basis for all successful treatment. However, in BD, correct
diagnosis and treatment (Figure 1) are especially complicated due to several features of
the disorder and patients (Figure 2). The most common misdiagnosis of bipolar patients is
thought to be unipolar depression, and several reasons for this can be suggested: the
first episode in BD is most often depression (Lish et al., 1994; Tondo et al., 1998; Judd
et al., 2003b; Morselli and Elgie, 2003), and especially BD II patients spend most of
their time in depression (Judd et al., 2002) and have several depressive episodes before
the first hypomania (Tondo et al., 1998). Thus, the patient may initially seek help for
depression and the switch or preceding bipolar picture may go unnoticed.
Delay from illness onset to the first contact with healthcare, from primary care to
psychiatric services, and from initial symptoms to treatment initiation (Kessler et al.,
1998; Goldberg and Ernst, 2002), might be several years in psychiatric disorders. The
diagnosis of BD appears to be made either during the first year of treatment or after a
long delay (Ghaemi et al., 1999; Ghaemi et al., 2000). In a multicenter European study,
the bipolar diagnosis in 71% of patients was set by a psychiatrist (Morselli and Elgie,
2003). Thus, for correct diagnosis to be made, the time to psychiatric treatment appears
crucial. In patients receiving a bipolar diagnosis with delay, the delay from onset of
illness to correct diagnosis was a mean of 5.7 years (Morselli and Elgie, 2003) or 8-10
years (Lish et al., 1994; Hantouche et al., 1998; Tondo et al., 1998; Ghaemi et al., 1999;
Ghaemi et al., 2000; Goldberg and Ernst, 2002; Baethge et al., 2003; Baldessarini et al.,
2003; Hirschfeld et al., 2003b). In a survey of bipolar members of the US National
Depressive and Manic-Depressive Association (Lish et al., 1994; Hirschfeld et al., 2003b),
one-third (34%) of respondents had had more than 10 years of treatment before receiving a
bipolar diagnosis. The delay from illness onset to treatment is 1-2.7 years longer for BD
II (Tondo et al., 1998; Baldessarini et al., 2003) and 1.3 years longer for women
(Baldessarini et al., 2003). The delay from first symptoms to mood-stabilizing treatment
is 8-10 years (Suppes et al., 2001; Goldberg and Ernst, 2002), being slightly longer for
BD II (Suppes et al., 2001). However, correct diagnosis does not equal correct treatment;
the factors correlating with unrecognized BD may also result in poor compliance to
treatment (Colom et al., 2005; Fleck et al., 2005; Vieta, 2005).
4.5.2 Undiagnosed bipolar disorder
The proportion of BD patients who remain undiagnosed is alarmingly high in various types
of cohorts. In two cohort studies (Ghaemi et al., 1999; Ghaemi et al., 2000) of bipolar
patients in inpatient or outpatient settings, the proportion of patients diagnosed
primarily at intake as unipolar was about 40%. In the French EPIDEP multicenter study
(Hantouche et al., 1998), the proportion of BD II patients increased from 22% to 40% when
a systematic evaluation of hypomania was conducted. In family practice, of the patients
screened for depression, 28/108 (26%) were diagnosed as bipolar with a semistructured
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instrument (DSM-III-R) (Spitzer et al., 1990b), and of these, 20/28 (71%) were previously
undiagnosed (Manning et al., 1997). In the Netherlands Mental Health Survey and Incidence
Study (NEMESIS), 73/136 patients (54%) went unrecognized because they had not contacted
healthcare or had failed to disclose their manic symptoms (ten Have et al., 2002). In the
Polish DEP-BI sample of 246 outpatients with recurrent major depression, 48/246 (19.5%)
were found to have previously unrecognized BD I and 86/246 (35.0%) BD II in a structured
interview (Kiejna et al., 2006). In a post-detoxification inpatient substance abuse
program for men, 85/295 patients (28.8%) had BD I or II, and of these, 42/85 (49%) had not
been previously diagnosed with BD (Albanese et al., 2006). MDD was the most commonly
assigned misdiagnosis (Albanese et al., 2006). In a Danish register study, 2315/4116
patients (56.2%) who at any time between the years 1994 and 2002 received a diagnosis of
BD got the diagnosis at the first treatment period, and 38.6% of patients who initially
had another diagnosis were diagnosed first as MDD patients (Kessing, 2005b); however, the
diagnoses were only made based on the register. In summary, bipolar patients with the
diagnosis may represent only a fraction of the subjects with the disorder, and the true
epidemiological extent of this problem awaits reliable estimation.
4.5.3 Differences between recognized and unrecognized bipolar disorder
patients
No clinical studies have been published in which the characteristics of clinically
unrecognized bipolar patients in psychiatric care are reported. The factors affecting use
of health services in general are well analyzed (Andersen, 1995). In studies reporting
reasons for delayed diagnosis or treatment of BD (Figure 3), delay was dependent on
illness characteristics [age at onset (Goldberg and Ernst, 2002), type I or II (Akiskal et
al., 2003; Baethge et al., 2003; Baldessarini et al., 2003), mood incongruent psychotic
features (Azorin et al., 2006), dysphoric mania (Akiskal et al., 1998; Dilsaver and
Akiskal, 2005), illness severity (Goldberg and Ernst, 2002; ten Have et al., 2002) or
course (Baldessarini et al., 2003)], patient characteristics like gender (Lish et al.,
1994; Baethge et al., 2003; Baldessarini et al., 2003; Hirschfeld et al., 2003b), race
(Bhugra and Flick, 2005), or cyclothymic temperament (Akiskal et al., 2003), communication
by the patient [insight, stigma, family history (Hambrecht, 1995), perceived need
(Mojtabai et al., 2002; ten Have et al., 2002), the burden experienced (ten Have et al.,
2002; Hirschfeld et al., 2003b)], and care provider [resources (Bhugra and Flick, 2005),
available time, diagnostic skills (Lish et al., 1994; Hirschfeld et al., 2003b)].
4.5.4 Consequences of missed diagnosis
The delays in diagnosis are alarmingly long considering the serious burden caused by the
delay and the adverse consequences of inappropriate treatment (Hantouche et al., 1998;
Baldessarini et al., 2003; Hirschfeld et al., 2003b). Undiagnosed bipolar patients may be
four times more likely to attempt suicide and 1.5 times more likely to be hospitalized
than diagnosed patients, generating considerable extra costs to society (Li et al., 2002;
Birnbaum et al., 2003; Shi et al., 2004). In a register study, 78% of unrecognized bipolar
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patients had serotonin-selective reuptake inhibitors (SSRIs) as monotherapy (Shi et al.,
2004) – unfortunately, also among the recognized patients, this proportion was 50%
(Birnbaum et al., 2003; Shi et al., 2004). However, treatment latency might not have an
effect on the efficacy of treatment. Shorter treatment latency has been connected to
greater morbidity before lithium treatment; while in treatment, the patients with shorter
treatment latency had better response but a similar proportional change in outcome as
patients with longer delay (Baldessarini et al., 1999).
4.5.5 Screening for bipolar disorder
At present, the Mood Disorder Questionnaire (MDQ) (Hirschfeld et al., 2000; Hirschfeld,
2001) appears to be the most useful screening instrument for detecting BD I and II.
Nevertheless, it may be somewhat less specific than originally intended (Hirschfeld et
al., 2000; Isometsä et al., 2003; Miller et al., 2004), without modification not be
optimally sensitive for BD II patients (Hirschfeld et al., 2003a; Isometsä et al., 2003;
Miller et al., 2004; Zimmerman et al., 2004), and some other screens may be better for
detecting bipolar spectrum. Use and development of different diagnostic screens for BD and
bipolar spectrum are useful not only for purposes of research, but also clinically to
improve correct and early diagnosis of BD and to direct diagnostic attention to patients
at the highest risk of BD. Thus, finding a suitable screen depends on the target group to
be screened as well as on the purpose of screening; for instance, high-risk adolescents
might require a different screen than that for depressed adult inpatients. However, a
diagnosis of BD should not be based exclusively on any screen, but on careful and often
repeated diagnostic evaluation, with several informants, and preferably with a prospective
follow-up of mood (Zimmerman et al., 2004; Akiskal and Benazzi, 2005; Baldassano, 2005;
Hirschfeld et al., 2005; Phelps, 2006).
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5. AIMS OF THE STUDY
We investigated the recognition, clinical characteristics, comorbidity, and outcome of 191
BD I and II patients with an acute phase in secondary level psychiatric care.
Specific aims of the study were as follows:
I   To obtain a comprehensive view of the clinical epidemiology of BD I and II in
    secondary level psychiatric settings.
II  To describe differences in current comorbidity between BD I and II and (unipolar)
    MDD, and between current and lifetime axis I and II comorbidities in BD.
III To investigate predictors of missed or incorrect clinical diagnosis of psychiatric
    patients with BD I and II.
IV  To investigate whether the course of BD type II is more depressive than that of BD I,
    and if so, the underlying factors causing this difference.
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6. METHODS
6.1 General study designs
The Jorvi Bipolar Study (JoBS) is a collaborative research project between the Department
of Mental Health and Alcohol Research of the National Public Health Institute, Helsinki,
Finland, and the Department of Psychiatry, Jorvi Hospital, Helsinki University Central
Hospital (HUCH), Espoo, Finland. The catchment area (pop. 261 116 in 2002) comprises the
adjacent cities of Espoo, Kauniainen, and Kirkkonummi, and the Department of Psychiatry at
Jorvi Hospital provides secondary care psychiatric services to the area’s residents. The
second report (Study II) also included major depressive disorder (MDD) patients from the
Vantaa Depression Study (VDS). The VDS was carried out in conjunction with the Department
of Psychiatry of the Peijas Medical Care District. The Ethics Committee of HUCH approved
the study protocol of VDS in 1996 and of JoBS in 2001.
Because of the different focuses of the studies, the publications had different patient
compositions as presented in Table 7.
Table 7. Composition of cohorts in the original publications
Cohort
          Jorvi Bipolar Study        Vantaa Depression Study         Total number
          (bipolar patients)         (major depressive patients)     of patients
Study I   Patients evaluated
          at baseline, N=191                                         191
Study II  Patients evaluated         Patients evaluated
          at baseline, N=191         at baseline, N=269              460
Study III Patients evaluated
          at baseline,
          excluding 8 BD NOS
          patients, N=183                                            183
Study IV  18-month follow-up,
          N=160                                                      160
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6.2 Screening
Using the Mood Disorder Questionnaire (MDQ), all in- and outpatients at the Department of
Psychiatry at Jorvi Hospital who currently had a possible new phase of DSM-IV BD were
sought from January 1, 2002 to February 28, 2003. During the given period, attending
mental health professionals at the Department of Psychiatry screened with MDQ every
patient aged 18-59 years who (1) was seeking treatment, (2) had been referred, or (3) had
already received care and was now showing signs of deteriorating clinical state, or a
change in mood in case of mania or hypomania. In addition, despite a negative MDQ screen,
patients were included as positive if suspected to have BD due to a clinical diagnosis of
BD or pertinent symptoms (N=28). A clinical diagnosis of ICD-10 schizophrenia was an
exclusion criterion for screening. Based on the pilot study of the JoBS (Isometsä et al.,
2003), the response to MDQ item 3 ("problems due to episodes") was ignored. The sampling
procedure is presented in Figure 3. After a positive MDQ screen, or suspicion of BD, the
patient was fully informed about the study project and written informed consent was
requested. Altogether, 1630 patients were screened, 546 of whom proved to be MDQ-positive
or suspected bipolar (Figure 3).
The detailed methodology of VDS has been reported elsewhere (Melartin et al., 2002). In
brief, JoBS was planned to be comparable with the VDS. In the VDS, patients were screened
for MDD in an acute mood episode, and all psychiatric patients aged 20-59 years 1) seeking
treatment, 2) referred to treatment, or 3) already in treatment with an acute
deteriorating clinical state were screened for MDD. The screening instruments in the VDS
included the five screening questions for major depression from the Schedules for Clinical
Assessment of Neuropsychiatry (SCAN) (Wing et al., 1990) and the Scale for Suicidal
Ideation (SSI) (Beck et al., 1979). The screen was considered positive if the patient had
a) one positive item among the five screening questions for depression from SCAN, or b) a
score of six or more on SSI (Beck et al., 1979). Exclusion criteria in the VDS included BD I
and schizophrenia. A total of 806 patients were screened; 703 screened positive, and
161/703 (22.9% of the screened) refused the interview.
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        Screened with Mood
        Disorder
        Questionnaire
        N = 1630
                                             Refused screening
                                             N = 46
        Positive MDQ with                    Screened negative
        response item 3                      N = 1038
        ignored (N=513),
        negative screen but
        a clinical diagnosis
        of BD (N=5) or
        attending personnel
        suspected BD
        (N=28)
                                             Refused face-to-face
                                             SCID-I interview
                                             N = 49
        Completed face-to-                   Could not be
        face SCID-I                          contacted
        interview                            N = 7
        N = 490
                                             Not bipolar
                                             N = 289
        Eligible bipolar
        patients
        N = 201
                                             Refused to participate
                                             or interrupted
                                             N = 10
        Included in JoBS
        N = 191
Figure 3. Screening of eligible bipolar patients in the Jorvi Bipolar Study 
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6.3 Baseline evaluation
6.3.1 Diagnostic measures
In the second phase of the JoBS, a diagnosis was made based on two separate interviews
using all available information from the face-to-face interviews and psychiatric records;
if the diagnosis was uncertain, attending personnel, family members, or other informants
were contacted. BD was diagnosed using the Structured Clinical Interview for DSM-IV
Disorders, researcher version with psychotic screen (SCID-I/P) (First et al., 2002). The
SCID-I was supplemented with a section for diagnosing mixed episodes. Of the 546 patients
with positive screens, 490 were interviewed (median delay from screening to interview 8.8
days), and 201 patients (12.3% of the screened, 38.4% of positive screens) were assigned a
diagnosis of BD after the SCID-I interview. The diagnosticians were all psychiatrists (OM,
HV, PA, KS, SL, Marita Pippingsköld), and weekly meetings were held to solve diagnostic
problems. Of previously diagnosed patients, 12 were not considered bipolar at interview, 9
refused to participate, and 6 could not be contacted. The patients who refused to
participate at some stage (N=105) were older than participants (median 44 vs. 37.7 years
for the cohort). The final study group included in the analyses consisted of 191 DSM-IV
bipolar I and II patients with a current phase. The current episode was defined according
to DSM-IV criteria and could be monophasic or polyphasic. Also included as bipolar II were
those bipolar NOS (not otherwise specified) patients with hypomania of 2-3 days, or
depressive mixed states (DMX3=three or more simultaneous intra-episode hypomanic
symptoms present for at least 50% of time during a major depressive episode) as defined by
Benazzi and Akiskal (Benazzi and Akiskal, 2001), that clearly belonged to the bipolar II
group. The soft bipolar spectrum was excluded.
Inter-rater reliability was tested using videotaped interviews that were then blindly
assessed by another diagnostician. In order not to reveal the diagnosis made by the first
interviewer, response to all items was requested and neither hints of inclusion or
exclusion nor the diagnosis were allowed on the tape. In the 20 randomly selected,
videotaped diagnostic interviews, agreement was complete (κ for BD overall= 1.0; also
specifically, bipolar I=1.0 and bipolar II=1.0).
In the second phase of the VDS, a current episode of MDD was diagnosed (and BD excluded)
using  the  World  Health  Organization  (WHO)   Schedules for  Clinical  Assessment  in 
Neuropsychiatry, version 2.0 (SCAN) (Wing et al., 1990). To exclude substance-induced mood
disorder, MDD patients who were currently abusing alcohol or other substances were
interviewed after two to three weeks of abstinence. The final study group included in the
analyses consisted of 269 MDD patients in VDS, all with a current episode. Inter-rater
agreement in diagnostic interviews was excellent (κ=0.86) (Melartin et al., 2002) .
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6.3.2 Observer and self-report scales
In the JoBS, only patients with BD were further evaluated. In the third phase, the current
symptomatology of the index episode was evaluated using the Young  Mania  Rating  Scale
(YMRS) (Young et al., 1978) and the 17-item Hamilton Depression Scale (Ham-D-17)
(Hamilton, 1960); the patient filled in the 21-item Beck Depression Inventory (BDI) (Beck
et al., 1961) and the Beck Anxiety Inventory (BAI) (Beck et al., 1988). In bipolar
patients, some delay occurred from screening to estimating symptom scores in the first
interview, which especially in case of short hypomanias meant that the patient had often
passed the index phase. In the analysis of symptom severity, these latter patients were
omitted; they were by interview euthymic (N=2) or had shifted to depression, but did not
fulfill the time criteria of two weeks (N=8).
6.3.3 Other characteristics
Information on demographic characteristics, variables for prior illness history, and
preceding treatment using a graphic retrospective life chart was collected. Age at illness
onset was defined as the time of onset of the first mood episode fulfilling DSM-IV
criteria. Age at treatment was the first contact with psychiatric care irrespective of
diagnosis; if this was not caused by a mood episode, the delay from episode to treatment
could be negative (N=5). Definitions of adequate acute-phase pharmacotherapy were based on
published treatment guidelines (Sachs et al., 2000; APA, 2002; Grunze et al., 2002;
Goodwin and Young, 2003; Grunze et al., 2003). The treatments were defined irrespective of
dosage, serum concentration, or duration of treatment as follows: 1. Adequate treatment
for bipolar depression – monotherapy with lithium or lamotrigine or combinations of
lithium, valproate, carbamazepine, or olanzapine with an antidepressant. The combination
of lamotrigine with an antidepressant was interpreted as inadequate treatment in bipolar I
patients. 2. Adequate treatment for mania/hypomania – monotherapy or combinations of
lithium, valproate, carbamazepine, atypical antipsychotics, or haloperidol. Treatment was
interpreted as inadequate if an antidepressant was used. 3. Adequate treatment for
mixed/depressive mixed state – defined the same as for mania, except that treatment was
interpreted as inadequate if a conventional antipsychotic was used. 4. Treatment for rapid
cycling – monotherapy or combinations of lithium, valproate, or carbamazepine. Treatment
with lamotrigine was interpreted as adequate for BD II patients. Treatment was classified
as inadequate if an antidepressant was used. At baseline, mood stabilizing treatment was
prescribed to 56% of patients (89/160) followed up for 18 months and to 87% of patients
(84/97) with a correct diagnosis of BD I or BD II. The adequacy of psychopharmacological
therapy at acute phase is described in detail elsewhere (Arvilommi et al., 2007), and
psychopharmacologic and psychosocial treatments during follow-up will be reported and
discussed in detail in a subsequent paper. Patients were rated as clinically recognized or
unrecognized. To avoid diagnostic bias caused by the study itself, the clinical bipolar
diagnosis had to have been made before the research MDQ screening.
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6.3.4 Assessing comorbidities in Study II
Current comorbid psychiatric diagnoses were assigned during an acute phase of MDD or BD.
However, in case of a manic or mixed episode severe enough to require hospitalization, the
second diagnostic interview was conducted when the patient was discharged from the
hospital, typically after about three weeks. The researcher made full DSM-IV axis I
diagnoses (SCID-I in JoBS, SCAN in VDS). Due to differences between the diagnostic tools
in the JoBS and the VDS, substance use disorders are comparable only concerning current
alcohol dependence, which also influences the total axis I comorbidity. The SCID-II for
DSM-III-R (Spitzer et al., 1990a) (VDS) or DSM-IV (First et al., 1997) (JoBS) personality
disorders was used to assess all comorbid diagnoses on axis II, which were modified for
between-group analyses in two diagnoses. Antisocial personality disorder was adapted to
DSM-IV criteria by deleting items "irresponsible parenting" and "failure to sustain a
monogamous relationship", and fusing two items exploring consistent responsibility from
DSM-III (VDS). DSM-IV borderline personality disorder was changed to DSM-III-R by
deleting item "stress-related paranoid ideation". This affected the prevalences in BD vs.
MDD comparisons, excluding no MDD patients with antisocial personality disorder, but 8
BD patients with borderline personality disorder were lost. Within the bipolar group,
unmodified DSM-IV criteria were used in within-group analyses.
6.4 Follow-up procedure
6.4.1 Study drop-outs
Of the total of 191 subjects with a current phase initially included in the study, at six
months, 5 (2.6%) refused to participate, 15 (7.9%) were missing, and 171 (89.5%) were
interviewed. Of missing patients, reliable information was available for 5 in patient
records. At 18 months, of the original sample of 191 patients, 3 were known to have died,
6 more refused to be interviewed, 142/188 (75.5%) were interviewed in person, and 5/188
were interviewed by phone. For 13 patients, information from patient records was
sufficient to construct a life chart, and another 3 patients with too short (less than 1
year) follow-up were excluded. Thus, 160/188 living patients (85.1%) were included in the
18-month analyses.
Of BD II patients, 7 converted to BD I due to mania, 3 due to a mixed phase during the
follow-up (between beginning of index phase and 18 months later). Gender distribution and
age of patients who had converted were similar to those who had not converted. In
analyses, all patients were treated according to their baseline diagnosis (results were
similar in alternative analyses with 18-month diagnoses). In addition, based on a similar
clinical picture, 8 BD NOS patients at intake were included in the analysis as BD II
patients. Of these BD NOS patients, 7 were followed up for 18 months, with two (29%)
converting to BD II.
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The patients included in the 18-month analysis were older (median 38.0 vs. 28.8 years,
U=1799.5, p=0.013), more often had professional education (105/160 (65.6%) vs. 10/31
(32.3%), χ12=12.1, p=0.001), had a longer duration of illness before intake (12.2 vs. 9.2
years, U=1924, p=0.048), and had an older age at first hospitalization (31.5 vs. 23.5
years, U=474, p=0.021) than patients not included in this analysis. No difference between
BD I and II was detected in the rate of attrition. Baseline characteristics of the 160 BD
patients who completed the 6- and 18-month follow-ups are shown in Study IV, Table 1. The
mean time to the 18-month follow-up interview in the total sample was 20.3±4.6 months, for
BD I 20.4±4.7 months and for BD II 20.2±4.6 months (t158=0.326, p=0.7) (Study IV, Table 1).
6.4.2 Integration of information into a life chart
After baseline assessments, the outcome was investigated at 6- and 18-month interviews,
which typically lasted 2-3 hours. Repeated SCID-I/P interviews and all observer- and
self-reported scales were included at both follow-up assessments. All medical and
psychiatric records were available. Besides information on symptom ratings and visits to
attending personnel, change points in the psychopathologic states were also inquired about
using probes related to important life events in order to improve the accuracy of the
assessment. All available data were then integrated into a graphic life chart based on
DSM-IV criteria, analogous to the life chart used in the VDS (Melartin et al., 2004). The
onset of index phase and the index episode were evaluated retrospectively.
6.4.3 Definitions for time periods of life chart
An episode, defined according to DSM-IV criteria, can be monophasic or polyphasic. Here, a
phase refers to a monophasic episode or a single phase of a polyphasic episode, and
similarly, an episode to a monophasic or polyphasic episode. A depressive, manic, or mixed
phase was defined as in DSM-IV; a hypomanic phase had a minimum duration of 2 days (Angst,
1998; Judd et al., 2003a; Akiskal and Benazzi, 2005). Depressive mixed phases (=three or
more simultaneous intra-episode hypomanic symptoms present for at least 50% of time
during a major depressive episode), as defined by Benazzi and Akiskal (Benazzi and
Akiskal, 2001), were also evaluated. A mood episode will be used here to mean any
monophasic depressive, manic, hypomanic, mixed, or depressive mixed phase, or a polyphasic
episode, ending when the full criteria of the final phase are no longer fulfilled.
Substance-induced mood episodes had the same definitions for a phase as above, but were
induced by any psychoactive substance; they were not included in the analyses of numbers
or durations of time periods. States of subsyndromal symptoms (including prodromal or
residual symptoms) were rated when the patient was not euthymic and did not fulfill the
criteria of a phase; durations of more than 1 week for hypomanic symptoms, and more than 2
weeks for depressive symptoms and cyclothymia were required. A state of euthymic mood was
used as a state variable when the duration of euthymia was more than 2 weeks.
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Time after the beginning of the index phase was divided into three periods: 1) mood
episode, 2) partial remission, or 3) full remission. In partial remission, while full
criteria of a DSM-IV mood episode were not met, some symptoms were present; in full
remission, no DSM symptoms were present. In statistical analysis, the patient had reached
remission if, as in the DSM-IV, in at least 2 consecutive months criteria were not met for
a mood episode. Relapse was defined as a return of a mood episode after a period of less
than 2 months with symptoms below the mood episode threshold. Recurrence was defined as
emergence of symptoms sufficiently severe to satisfy criteria for a new mood episode after
at least 2 consecutive months of partial or full remission.
Figure 4. Definitions for time periods of life chart; an example of a monophasic patient 
with full remission
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Figure 5. Definitions for time periods of life chart; an example of a polyphasic patient
with partial remission preceding full remission
6.4.4 Principal outcome measures
Five principal outcome measures were evaluated (Figures 4 and 5). 1) The proportion of
time in different symptom states during follow-up is time spent in any state divided by
the duration of follow-up. 2) Time with full criteria of the index phase was counted from
the onset of the index phase to a state not fulfilling the full criteria of that phase.
3) Time with full criteria of the index episode was counted from the onset of the index
episode to the end of the last phase that met the criteria of a depressive, manic,
hypomanic, mixed, or depressive mixed phase. 4) Time to full remission is time from the
beginning of the index phase to onset of a state of full remission lasting at least 2
consecutive months. 5) Time to recurrence from the beginning of remission is the time from
onset of remission lasting at least 2 consecutive months to onset of a new episode.
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6.5 Statistical methods
The Pearson’s chi-square statistic and Fisher’s exact test were used to evaluate categorical
and nonparametric data, the Mann-Whitney U-test or Kruskall-Wallis test to compare
continuous variables not normally distributed, and the two-sample t-test for continuous
variables normally distributed. Logistic regression models were used to adjust for
confounding factors. Only those who completed the whole 18-month follow-up were included
in the analyses of outcome. Despite multiple testing, for descriptive purposes, the results
in univariate analyses are reported as significant at p≤0.05. The logistic regression models
(Study I, II, and III) or the Kaplan-Meier analyses, Cox models, and linear regression
models (Study IV) constitute the main findings. SPSS software, version 11.0 or 12.01, was
used.
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7. RESULTS
7.1 Clinical characteristics of bipolar I and II disorders (Study I)
The final sample consisted of 90 bipolar I and 101 bipolar II patients (Table 8), the
latter including eight bipolar NOS patients. Overall, approximately half (52.9%) of the
patients were women; significantly more men had BD I and women BD II. The mean age of the
cohort was 37.7 years, and BD I patients tended to be older than BD II patients (Table 8).
The men were significantly older. Every fourth patient (25.7%) was divorced or widowed.
Two of five patients (39.8%) had no professional education, BD I less than BD II; on the
other hand, one of six patients (16.2%) had university-level education, BD I more often.
7.1.1 Analysis of screening
The effect of the ignored response to MDQ item 3 (distress from symptoms) in the sample
was evaluated. Of the cohort, 18% of BD I and 27% of BD II patients would have been
excluded using the standard cut-off of 3-4 in item 3 (1 BD I and 4 BD II patients
responded "1"; 15 BD I and 23 BD II patients responded "2"), and 38 patients had left the
item unanswered. Overall, two of five patients (42%) would have gone undetected without
the modification. The screening considerably increased the detection rate of BD, by an
estimated 51%.
7.1.2 Clinical history
An average patient in the cohort had an age at onset of about 20 years and now, being near
40 years, had gone through about 5 lifetime episodes (Table 8). Over half (58.4%) of BD II
and a quarter (25.6%) of BD I patients had no prior hospitalizations, with BD I patients
having more hospitalizations. Most patients (85%) had had at least one polyphasic episode
during their lifetime. BD I patients had accumulated more (hypo)mania and polyphasic
episodes than BD II patients. Lifetime psychotic symptoms were reported in half (N=95/191,
49.7%) of the cases, twice as often in BD I (Table 8).
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Table 8. Main differences between BD I and BD II in the Jorvi Bipolar Study in 
sociodemographic and clinical characteristics at intake (N=191) 
 BD I            BD II           Total BD Test of significance
Characteristics 1  (N=90) (N=101) (N=191) Test statistic p
Sociodemographic
characteristics
Male                                50 (55.6%)      40 (39.6%)      90 (47.1%)      χ2=4.86, df=1       p=0.027
Age at entry, years                 39.5±12.0,37.9  36.0±12.1,35.0  37.7±12.1,36.5                      NS
Not cohabiting                      25 (27.8%)      36 (35.6%)      61 (31.9%)                          NS
No professional education           30 (33.3%)      46 (45.5%)      76 (39.8%)                          NS
Disability pension                  28 (31.1%)      15 (14.9%)      43 (22.5%)      χ2=7.2, df=1        p=0.007
Family history of BD                15 (16.7%)      22 (21.8%)      37 (19.4%)                          NS
Illness characteristics
Age at onset of first episode, years 24.1±10.5,21.2  23.3±9.2,21.2   23.7±9.8,21.2                  NS
Number of lifetime phases      18.9±35.1,10   16.1±21.5,10    17.4±28.7,10.0                 NS
Number of lifetime major
depressive phases 8.0±13.2,5.0  8.0±11.1,5.0    8.0±12.1,5.0                  NS
Psychotic symptoms during lifetime  62 (63.9)       35 (36.1)       97 (50.8)       χ2=22.2, df=1 p<0.001
History of treatment
Age at psychiatric care, years      30.6±10.8,27.3 30.6±11.4,27.4  30.6±11.1,27.3                      NS
Age at first hospitalization, years 32.3±10.7,30.6  32.9±10.6,32.9  32.6±10.6,31.4                      NS
Number of hospitalizations
if hospitalized                     5.2±6.3,3.0     2.9±3.1,2.0     4.3±5.4,2.0     U=953.5, Z=-2.89    p=0.004
No previous hospitalization         23 (25.6%)      59 (58.4%)      82 (42.9%)      χ2=21.0, df=1 p<0.001
Delay from first episode to
treatment, years                    6.5±9.0,2.6     7.3±9.3,4.2     6.9±9.1,3.5                         NS
Correct diagnosis of BD
No bipolar diagnosis    23 (25.6%)      51 (50.5%)      74 (38.7%)      χ2=12.7, df=1   p<0.001
Age at diagnosis, years     35.4±10.9,32.2 35.2±11.6,34.7  35.3±11.2,33.5                 NS
Delay from first episode to
diagnosis, years     9.7±9.7,7.0   12.3±9.7,9.9    10.8±9.6,7.8                   NS
Delay from first contact to
psychiatric care to diagnosis, years 4.6±6.0,3.0   5.7±7.9,2.3     5.1±6.9,2.7                    NS
Characteristics at intake 
Current episode                                                                                         NS
    Depression    15 (16.7%)      27 (26.7%)      42 (22.0%)
    Hypomania    2 (2.2%)        9 (8.9%)        11 (5.8%)
    Mania     20 (22.2%)      NA              20 (10.5%)
    Mixed 2     7 (7.8%)        13 (12.9%)      20 (10.5%)
    Polyphasic    46 (51.1%)      52 (51.5%)      98 (51.3%)
Psychotic symptoms currently        20 (22.2%)      11 (10.9%)      31 (16.2%)      χ2=4.49, df=1 p=0.034
Rapid cycling preciding intake      28 (31.1%)      34 (33.7%)      62 (32.5%)                          NS
Beck Depression Inventory score
of depressive patients              26.7±9.3        25.7±9.8        26.2±9.6                            NS
Hamilton Depression Rating Scale
score of depressive patients        21.9±5.6        20.2±7.4        21.0±6.7                            NS
Young Mania Rating Scale of
manic and hypomanic patients        20.6±12.8       14.4±5.1        18.7±11.3                           NS
1    N (%) or mean±standard deviation, median, NS=nonsignificant
2    Mixed episode in BD I and depressive mixed state in BD II
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7.1.3 Missing clinical diagnosis and delays in diagnosis
Clinical history revealed two major delays: in seeking treatment and in achieving the correct
diagnosis (Table 8). The former explains a major part of the latter, but the pre-diagnosis
treatment time was still considerable. Diagnosed BD II patients had a longer delay from
the first episode to diagnosis than BD I patients, but there was no difference in median
delay from treatment to diagnosis or delay range. More strikingly, a quarter (25.6%) of BD
I patients were previously undiagnosed, and over half (50.5%) of BD II patients. Men were
more often diagnosed than women (74.4% vs. 49.5%). The disparity between BD I and II
remained after adjustment for gender.
7.1.4 Current episode and phase
Half (51.3%) of the patients were currently in a polyphasic episode. Rapid cycling
accounted for one-third (32.5%) of the cohort. The distribution of phases was different
in mono- and polyphasic episodes in BD I patients; mania seemed to be principally
monophasic in the index episode – only 3/23 episodes were polyphasic. Current psychotic
symptoms were observed in 16.2% of patients, more in BD I (Table 8). More BD I than BD II
patients were currently hospitalized; still, over half of BD I subjects were outpatients.
Most mixed BD I patients (N=11/15, 73.3%) as well as some manic patients (N=6/23, 26.1%)
were treated in outpatient settings. Despite similar symptom severity, more depressive BD
I patients were hospitalized than depressive BD II patients (46.8% vs. 25.4%).
7.1.5 Symptom severity
In depression, the symptom scores differed only according to the treatment setting, not
the type of BD (Study I, Table 4). The YMRS score was, as expected, higher in mania than
hypomania. In a mixed phase in BD I and a depressive mixed phase in BD II, BAI scores were
significantly higher than in other phases or in purely depressed patients.
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7.2 Differences in axis I and II comorbidity between bipolar I
and II disorders and major depressive disorder (Study II)
7.2.1 Comorbidity in bipolar disorder versus major depressive disorder
Nearly all comorbid disorders had a slightly different distribution in BD patients than in
MDD patients. In univariate analyses, MDD had significantly more current comorbid axis I
disorders (69.1% vs. 57.1%), anxiety disorders, and cluster A and C personality disorders.
BD had more eating disorders, somatoform disorders, and cluster B personality disorders.
More MDD patients had phobic anxiety disorders (BD I vs. BD II vs. MDD 20.0% vs. 26.7% vs.
37.9%, respectively; χ22=11.6, p=0.003), also when comparing only depressed MDD and BD
patients.
In nominal regression models with the main categories of comorbidity, after adjusting for
level of depression, gender, and age, the differences in anxiety disorder, eating
disorder, and personality clusters A and B remained significant (Table 9). The other
aspects of severity had no effect on the results and were thus omitted from the final
model.
Table 9. Multinomial regression model for current axis I comorbidity 
in 269 unipolar depressive patients in the Vantaa Depression Study and 
191 bipolar patients in the Jorvi Bipolar Study
Variable Unipolar 1 BD II Wald     p BD I Wald     p
OR OR 95%CI χ2                 OR 95%CI χ2
Sociodemographic
characteristics
   Age  1.0    0.98  0.96-1.0    4.0      0.05      1.00  0.98-1.02    0.036    0.85
   Gender                   1.0         2.0   1.2-3.4     6.8      0.009     3.3   1.9-5.7      17.6   <0.001
Clinical status
   Beck Depression Inventory 1.0         0.96  0.93-0.98   10.9     0.001     0.94  0.91-0.95    20.1   <0.001
Axis I 
   Any anxiety disorder      1.0         0.90  0.54-1.5    0.18     0.67      0.54  0.31-0.95    4.5      0.03
   Any eating disorder       1.0         30.9  5.8-163.7   16.3   <0.001      21.4  3.2-140.9    10.1     0.001
Axis II
   Cluster A    1.0   0.28  0.12-0.65   8.7      0.003     0.26  0.11-0.063   9.1      0.003
   Cluster B   1.0   2.3   1.1-4.6     5.2      0.02      6.1   3.0-12.4     25.5   <0.001
1 Reference category
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7.2.2 Comorbidity in bipolar disorder
The  overall current  (Table 10) and lifetime  (Table 11) comorbidity in BD was high. In BD
patients overall, 69.8% had a current comorbid disorder (unmodified proportions, see
methods); on axis I 60.2% (BD I 54.4%, BD II 65.3%) and on axis II 42.9% (42.2%, 43.6%,
respectively). Anxiety disorders were currently present in 44.5%, substance use disorders
in 19.9%, and eating disorders in 7.9% of BD patients. BD II patients had more anxiety
disorders, posttraumatic stress disorder, and binge eating. In a logistic regression model
with BD I and II, after adjusting for gender, age, and Beck Depression Inventory findings,
no significant differences emerged. In substance use disorders, current prevalences were
one-third of lifetime prevalences, but in anxiety disorders these two rates were rather
consistent.
The comorbidity in BD was distributed according to current illness phase (Study II, Table
4). Manic and hypomanic patients had the lowest prevalences in all main categories of
disorders, and mixed and depressive mixed patients combined the highest, with prevalences
of total comorbidity of 56.8% and 82.9%, respectively. One-fifth of (hypo)manic patients
had an anxiety disorder. This proportion was twofold in depressive and threefold in mixed
patients.
Table 10. Current DSM-IV axis I and II comorbidity in 191 bipolar patients in 
the Jorvi Bipolar Study
BD I BD II Total BD
(N=90) (N=101) (N=191)
                                N       %                N       %                N       %
Any comorbid axis I diagnosis   49      54.4             66      65.3    115     60.2
Any anxiety disorder 1   32      35.6             53      52.5             85      44.5
   Panic disorder         17      18.9             29      28.7             46      24.1
   Agoraphobia without panic    3       3.3              1       1.0              4       2.1
   Social phobia               13      14.4             21      20.8             34      17.8
   Simple phobia                5       5.6             10       9.9             15       7.9
   OCD                          3       3.3              1       1.0              4       2.1
   PTSD 2                       5       5.6             15      14.9             20      10.5
Eating disorder                 4       4.4             11      10.9             15       7.9
   Bulimia                      3       3.3              6       5.9              9       4.7
   Anorexia                     1       1.1              0       0.0              1       0.5
   Binge eating 3               0       0.0              5       5.5              5       2.6
Any somatoform disorder         3       3.3              6       5.9              9       5.2
Substance use disorder         19      21.1             19      18.8             38      19.9
   Alcohol abuse                3       3.3              3       3.0              6       3.1
   Alcohol dependence          15      16.7             12      11.9             27      14.1
   Drug abuse                   0       0.0              1       1.0              1       0.5
   Drug dependence              1       1.1              3       3.0              4       2.1
No comorbid axis I or II 
disorder   30      33.3             26      25.7             56      29.3
1 χ2=5.5, df=1, p=0.019
2 χ2=4.4, df=1, p=0.036
3 χ2=4.6, df=1, p=0.032
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Table 11. Lifetime DSM-IV axis I and II comorbidity in 191 bipolar patients in 
the Jorvi Bipolar Study
BD I BD II Total BD
(N=90) (N=101) (N=191)
                                N       %                N       %                N       %
Any comorbid axis I diagnosis  73      81.1             77      76.2            150      78.5
Dysthymia                       5       5.6              5       5.0             10       5.2
Any anxiety disorder 1   41      45.6             61      60.4            102      53.4
   Panic disorder              24      26.7             37      36.6             61      31.9
   Agoraphobia without panic    4       4.4              2       2.0              6       3.1
   Social phobia               19      21.1             31      30.7             50      26.2
   Simple phobia                6       6.7             10       9.9             16       8.4
   OCD                          4       4.4              5       5.0              9       4.7
   GAD                         12      13.3             17      16.8             29      15.2
   PTSD 2                       8       8.9             23      22.8             31      16.2
Eating disorder                10      11.1             21      20.8             31      16.2
   Bulimia                      9      10.0             14      13.9             23      12.0
   Anorexia                     4       4.4              2       2.0              6       3.1
   Binge eating 3               0       0.0              5       5.0              5       2.6
Substance use disorder        52      57.8             45      44.6             97      50.8
   Alcohol abuse               11      12.2              7       6.9             18       9.4
   Alcohol dependence          39      43.3             36      35.6             75      39.3
   Drug abuse                   2       2.2              1       1.0              3       1.6
   Drug dependence              5       5.6              7       6.9             12       6.3
Any comorbid axis II diagnosis  38      42.2             44      43.6             82      42.9
   Cluster A                   10      11.1              9       8.9             19       9.9
   Cluster B                   28      31.1             26      25.7             54      28.3
   Cluster C                   18      20.0             26      25.7             44      23.0
No comorbid axis I or II
disorder        11      12.2             20      19.8             31      16.2
1 χ2=4.2, df=1, p=0.04
2 χ2=6.7, df=1, p=0.009
3 χ2=4.6, df=1, p=0.032
7.3 Clinical predictors of unrecognized bipolar I and II
disorders (Study III)
In   univariate  analyses,  diagnostic  status  was  found  to  be  related  to  gender.  In  BD I,
unrecognized patients had a higher work status, with a disability pension ten times less
common than in recognized patients (4.3% vs. 41.8%, χ32=11.6, p=0.009). In BD II,
unrecognized patients were more often professionally educated (66.0% vs. 43.5%, χ12=4.7,
p=0.029). No other sociodemographic differences were observed.
In BD I patients, the clinical factors associated with poor recognition in univariate
analyses (Study III, Table 1) were lower age at first symptoms and age at onset, rapid
cycling, less manic and more depressive episodes, more lifetime anxiety disorder, and less
lifetime substance use disorder. Unrecognized BD I patients had a longer delay from
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illness onset to psychiatric treatment, shorter time in treatment, and less
hospitalizations (all had had hospitalizations only in depressed or mixed episodes) than
their recognized peers. In BD II patients, lack of psychotic symptoms, fewer depressive
episodes, and shorter time in treatment were correlated with missed bipolar diagnosis.
In final models explaining unrecognized BD type I (Study III, Table 2), rapid cycling (OR=
11.6), no hospitalizations (OR=10.6), and no psychotic symptoms (OR=4.4) remained
significant. In BD II patients (Study III, Table 3), no psychotic symptoms (OR=3.3),
female gender (OR=3.0), and shorter time in treatment (OR=1.1) predicted unrecognized BD.
7.4 Outcome of bipolar disorder (Study IV)
7.4.1 Proportion of time in different symptom states during follow-up
The proportions of time spent in most states differed according to type of disorder (Table
12). BD II patients spent a significantly greater proportion of time in any mood episode
and in a depressive phase or depressive symptoms. BD I patients spent more time euthymic.
No differences were detected between BD I and BD II patients in the proportions of time
spent in manic/hypomanic or mixed/depressive mixed states when different degrees of states
were considered together.
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Table 12. Differences between BD types I and II in proportion of time spent in specific 
clinical states and mean number of new specific states in 160 bipolar patients
followed up for 18 months
 BD I            BD II           Total BD
 (N=75) (N=85) (N=160) Test statistic p
Proportion of time spent in specific states during follow-up, mean %
Any mood episode     37.7            47.5            42.9            U=2508              0.02
Depressive states   41.7            58.0            50.4            U=2306              0.003
   Major depressive phases 1      29.0            38.7            34.2            U=2357              0.004
   Depressive symptoms 2          12.7            19.3            16.2            U=2384              0.005
Hypomanic and manic states        5.5             5.7             5.6                                 NS
   Manias 3,4                  2.7             0.8             1.7             U=2341              <0.001
   Hypomanias 5                   2.1             4.1             3.2             U=2567              0.02
   Hypomanic symptoms 2           0.7             0.8             0.8                                 NS
Mixed states                      3.9             3.9             3.9                                 NS
   Mixed phases 3,4               2.1             0.6             1.3             U=2551              <0.001
   Depressive mixed phases 6      1.7             3.4             2.6             U=2681              0.02
Euthymic phases 3                 48.7            31.7            39.6            U=2279              0.002
Other states                      49.0            32.4            40.2            U=2319              0.003
   Cyclothymic phases 3           0.3             0.5             0.4                                 NS
   Substance-induced mood
      episodes 3                  0.0             0.2             0.1                                 NS
Mean number of new phases according to type of phase 7
Mean number of new episodes       2.4             3.2             2.8                                 NS
Mean number of new phases         0.82            0.87            0.8                                 NS
Mean number of specific phases
   Major depressive 1             1.11            1.69            1.42            U=2400              0.006
   Manic 3,4                      0.28            0.096           0.18            U=2649              0.004
   Hypomanic 5                    0.61            1.7             0.86                                NS
   Mixed 3,4                      0.19            0.060           0.12            U=2758              0.005
   Depressive mixed 6             0.19            0.24            0.22                                NS
1  Phases defined using DSM-IV criteria, separated depressive mixed phases
2  Symptoms without full DSM-IV criteria, including prodromals and residuals
3  DSM-IV criteria
4  Patients with a switch from BD II to BD I during follow-up included
5  DSM-IV criteria, except duration of 2 days accepted
6  Three or more simultaneous intra-episode hypomanic symptoms present for at least 50% of time during a major depressive phase;
   the states not included in depressive states
7  Weighted with time in follow-up; Mann-Whitney U-test
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7.4.2 Factors underlying more time ill
Most  patients  (78.1%)  had  new  phases  (of  a  polyphasic  episode,  relapse or recurrence)
during the follow-up; no differences in the number of new episodes or phases overall were
observed between BD I and II patients (Table 11). However, more BD II patients had a new
depressive phase, and they also had a greater number of depressive phases (Table 11). When
manias and hypomanias as well as mixed and depressive mixed phases were considered
together, no differences between BD I and II patients were detected in the presence or
number of these phases. While the index phase was most often a major depressive episode
with similar proportions in BD I and II (Study IV, Table 1), subsequent phases also
comprised mainly depressions, but more so in BD II. The duration of a depressive phase did
not differ between BD I and II, and the same was true for all other states, with the
exception of euthymia (Study IV, Table 3). When only patients with a depressive index
phase were compared, no differences were detected between BD I and II in the numbers of
new phases, episodes, or depressions. However, among patients with other than depressive
index phases, BD II patients had a significantly higher number of new phases and
hypomanias than BD I patients.
The proportion of all patients meeting full criteria of a mood episode until the end of
follow-up was one of ten (11.3%); one-third (33.1%) did not reach full remission (Study
IV, Figure 1), and three-quarters (73.2%) of patients with full or partial remission had a
relapse or recurrence. More BD I than II patients reached full remission (BD I vs. BD II
76.0% vs. 58.8%, χ12=5.7, p=0.017), and a greater proportion of BD II patients reached at
best only partial remission (12.0% and 30.6%, respectively, χ12=8.7, p=0.003).
7.4.3 Other principal outcome measures
Median time with full criteria of the index phase overall was 3.5 months and median time
with full criteria of the index episode overall was 8.5 months. No difference between
BD I and II patients was evident in the duration of index phase or episode, both of which
were mainly determined by the type of index phase. Also, median durations of distinct types
of phases did not differ between BD I and II. Median time to full remission (lasting at
least 2 consecutive months) from the beginning of the index phase was overall 11.1 months
(Study IV, Table 3). BD II patients needed 3.0 months more to achieve full remission,
but the difference was not statistically significant. Median time to recurrence after 2 
months of (full or partial) remission was 8.9 months (Study IV, Table 3).
7.4.4 Effect of index phase
Type of index phase had a significant effect on most outcome measures. Type of index phase
affected the proportion of time in different symptom states (Study IV, Table 4). Patients
with a depressive or depressive mixed index phase had the highest proportion of time spent
in any mood episode and in depressive states during follow-up. Patients with a manic index
phase spent the smallest proportion of time ill, in any depressive states, and in mixed
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plus depressive mixed phases. Moreover, they spent 72.2% of time euthymic compared with
34.4% in patients with a depressive index phase during follow-up. Patients with a
hypomanic and mixed phase were in an intermediate position compared with other phases. A
depressive index phase had the longest and a hypomanic index phase the shortest duration
(Study IV, Table 3). Mixed index phases were more similar to depressive index phases than
to manic phases in all principal outcome measures, with no statistically significant
differences in post hoc analyses between depressive and mixed index phases. Full remission
during the 18-month follow-up was most prevalent after mania (Study IV, Table 5). In
addition, patients with a manic index phase had the least new phases, episodes, and
specifically, depressive and hypomanic phases in follow-up (Study IV, Table 4).
7.4.5 Effect of a polyphasic episode at intake
Polyphasic index episodes were detected overall (at baseline or continuing from intake) in
103/160 patients (64.4%), with no (statistically) significant differences being present
between BD I and II patients. Different types of index phases were preceded and followed
by a polyphasic episode with different distributions, and this was an important modifying
factor in outcome. Only one-fourth of manic index phases were polyphasic (either preceding
or continuing from intake), in contrast to all other phases (χ32=18.4, p<0.001) (Study IV,
Figure 2). While a depressive index phase was most likely to be polyphasic preceding the
index phase (χ32=14.5, p=0.002), mixed and depressive mixed index phases were most likely
to continue being polyphasic (χ32=13.7, p=0.003).
7.4.6 Effect of clinical diagnosis and adequate acute-phase pharmacotherapy
at intake on principal outcome measures
In the total sample, having a clinical diagnosis of BD at intake had a significant
influence on outcome only in one measure, time to full remission, which was significantly
longer for clinically undiagnosed patients. Comparing diagnosed BD I and II patients,
median duration of index episode, time to recurrence after 2 months of remission, and
proportion of time ill (31.8% vs. 50.8% U=767, Z=-2.8, p=0.005) showed better outcome for
BD I. Accordingly, BD I patients with adequate acute-phase pharmacotherapy had a better
outcome than BD II patients with adequate pharmacotherapy in terms of time to full
remission. Comparing undiagnosed BD I and II groups, time to full remission was the only
statistically significant difference, being longer for BD I. No differences were detected
between inadequately treated BD I and II.
BD I patients with a diagnosis and adequate acute-phase pharmacotherapy did better than
undiagnosed or inadequately treated BD I patients. Duration of index phase, duration of
index episode, time to full remission, and proportion of time ill (21.4% vs. 50.7%, U=327,
Z=-2.7, p=0.008) showed better outcome for the diagnosed BD I patients, even more than
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duration of index episode, time to full remission, and proportion of time ill (21.4% vs.
46.2%, U=479, Z=-2.2, p=0.025) for adequately treated BD I patients. Surprisingly, no
differences were found when comparing diagnosed BD II with undiagnosed BD II, or
adequately treated BD II with inadequately treated BD II.
7.4.7 Linear regression models and survival analyses of differences between
bipolar I and II patients in the five principal outcome measures
A linear regression model was constructed for the proportion of time in different symptom
states during follow-up; the differences between BD I and II did not reach significance.
Two similar linear regression models were then created explaining, specifically, time in
depressive states (Table 13). In the first model, the effect of index phase was controlled
for dimensionally (with baseline HAM-D and YMRS scores), and in the second model,
categorically (major depressive vs. other phase); in both, all nonsignificant variables
except age and gender were removed. In both models, BD II predicted more time in
depressive states. Besides having BD II, higher number of comorbid axis I disorders, and
in the final dimensional model, also higher HAM-D score, and in the final categorical
model, depressive index phase significantly and independently predicted higher proportion
of time in depressive states.
For the four other principal outcome measures (time with full criteria of the index phase,
time with full criteria of the index episode, time to full remission from the beginning of
the index episode, and time to recurrence from the beginning of remission), Kaplan-Meier
models and Cox regression models, adjusted for age and gender, gave no statistically
significant differences between BD I and II.
Table 13. Linear regression models with type of index phase controlled for dimensionally 
and categorically for total time spent in depressive symptoms or major depressive phases 
during 18-month follow-up of 160 BD patients
                                B            SE           Beta t             p
Dimensional model
Type I or II disorder  13.7          5.0          0.2             2.8          0.007
Age                          0.22          0.21         0.076           1.1          0.29
Gender                       5.0           5.0          0.072           1.0          0.32
HAM-D score at baseline      1.7           0.31         0.39            5.4         <0.001
Number of axis I disorders   6.1           3.1          0.15            2.0          0.048
Categorical model
Type I or II disorder        10.8          5.2          0.16            2.1          0.038
Age                          0.24          0.22         0.08            1.1          0.28
Gender                      5.2           5.1          0.075           1.0          0.31
Index phase MDE              19.8          5.0          0.29            4.0         <0.001
Number of axis I disorders   11.2          3.1          0.027           3.6         <0.001
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8. DISCUSSION
8.1 Main findings
Even  in  this  psychiatric  setting,  BDs were usually either unrecognized or recognized only
after a long delay. A significant proportion of not only BD II, but also BD I patients had
never been hospitalized. Furthermore, polyphasic episodes and rapid cycling were commonly
present among both BD I and II patients. Depressive mixed states were at least as common
among BD II patients as mixed episodes among BD I patients.
Patterns of psychiatric comorbidity of BD and MDD differed somewhat qualitatively. MDD
patients had more current axis I disorders, specifically anxiety disorders, and more
cluster A personality disorders. In contrast, BD patients had more cluster B personality
disorders. BD I and II patients were quite similar in comorbidity. Among BD patients, the
prevalence of psychiatric comorbidity was strongly associated with the current illness
phase.
The classic presentations of BD with hospitalizations, manic episodes, and psychotic
symptoms lead clinicians to correctly diagnose BD I in psychiatric care. When the classic
presentations are absent, as in BD II patients, but also in a large proportion of BD I
patients, the disorder is recognized less often. Time of follow-up elapsed in psychiatric
care but none of the clinical features seemed to explain correct diagnosis of BD II,
suggesting reliance on cross-sectional presentation of illness. In addition, rapid cycling
among BD I patients and female gender among BD II patients were correlated with
unrecognized BD. It is noteworthy that of unrecognized BD patients, only one-third had
ever been hospitalized, and four-fifths were currently outpatients. Thus, the problems in
diagnosis were most evident in outpatient settings.
In medium-term follow-up, BD II patients spent about 40% more time depressed than BD I
patients. The most important factors explaining this difference were higher proportions of
BD II than BD I patients having depressive phases, a higher proportion of depressive
phases among all phases in BD II, and a higher frequency of depressive phases in BD II
during follow-up.Duration of the depressive phases was, however, equal. Although type of
index phase was a major determinant of medium-term illness course, the finding of BD II
patients spending more time in depression persisted even after controlling for this
confounding factor.
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8.2 Methods
The Jorvi Bipolar Study (JoBS) is the first clinical cohort study based on systematic
screening for BD among psychiatric in- and outpatients within a geographically defined
catchment area. The data on unrecognized BD are thus uniquely representative, and
comparisons between BD I and II are unbiased by sampling. This is the first study to
compare total axis I and II comorbidity between MDD, BD I, and BD II patients. The
sampling of patients at the beginning of a new phase enabled investigation of the duration
of different types of index phases and the effect of index phase on other outcome measures
and comorbidity. No other study has contained patients with all types of index phases,
including hypomanias and depressive mixed phases. The outcome of BD I and II has been
compared in only a few cohorts.
8.2.1 Representativeness of the cohort sample
The present naturalistic study involved a relatively large (N=191) cohort that was
representative of secondary care psychiatric BD patients with a new phase of BD, including
both BD I and II, independent of clinical diagnosis. Finland has no private psychiatric
hospitals, and public psychiatric care is free of charge. Probably, most BD I patients
seek treatment or contact a psychiatrist in an acute phase, while more BD II patients may
be treated by primary healthcare or private psychiatrists. Using the MDQ screen was a
major strength of the study; most BD patients in psychiatric care in the area with an
incident illness episode were likely found. After interviewing also patients with a
previous clinical diagnosis or suspicion of BD, screening was more sensitive to patients
with worse insight into the illness. Nevertheless, it is impossible to exclude the
possibility that individual undiagnosed patients lacking insight or denying their illness
might have remained undetected due to their consistent denial of all symptoms in the
screen and diagnostic interviews. However, in order to significantly bias the findings,
such cases would need to be numerous and also have characteristics markedly different from
the current cohort. This possibility thus seems remote and merely theoretical. Moreover,
the rate of refusals was low, estimated not to exceed 10% of all BD patients.
8.2.2 Screening
A large number of psychiatric patients (N=1630) were screened. The MDQ was used, but in
order to increase sensitivity for BD II, the cut-off was modified by including as positive
also patients without problems due to episodes. This modification of the cut-off in the
screen was based on the pilot study of the JoBS (Isometsä et al., 2003), some other
studies (Benazzi, 2003; Miller et al., 2004; Zimmerman et al., 2004), and the definition
in the DSM-IV that hypomania is not severe enough to cause marked impairment in
functioning. The higher sensitivity but lower specificity of the modified MDQ resulted in
a higher number of false positives to be excluded in the SCID interview.
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At the time of the study, the MDQ was the best instrument available to screen for BD. Using
a screen profoundly influenced the composition of the sample compared with previous
studies. Had the sampling been based on the specific type of current episode, the size of
the cohort compared with its actual size would have been 16% for psychotic symptoms, 56%
for depression, and 22% for mixed episodes. Based on inpatient status, 34% of patients
would have been included, and based on clinical diagnosis 61%.
8.2.3 Diagnostic measures
All diagnoses were carefully assigned by psychiatrists with a minimum of 5 years of
clinical experience using a semistructured interview (First et al., 2002), information
from all patient records was available and completed with several informants in any case
of uncertainty, and interrater reliability was assessed and found to be excellent (kappa
1.0 for both BD I and II). This kind of diagnostic procedure has been used as a golden
standard in studies evaluating the validity of SCID-I (Shear et al., 2000), and thus
evaluated, the BD I diagnosis should be both highly reliable and valid. The reliability of
SCID-I for DSM-III-R BD was 0.84 (Williams et al., 1992); in the only study comparing the
validity of diagnosis of BD by SCID the kappa was 0.89 (Fennig et al., 2004). The
reliability or validity of SCID for BD II has not been evaluated. The reliability of SCID-
II using DSM-IV criteria has been evaluated in one study to be from 0.83 to 0.98 for
distinct disorders, but the validity was poor (Skodol et al., 1988); however, the number
of patients in the study was only 22 (see also www.scid4.org). The SCID is the most
commonly used and best validated diagnostic instrument in psychiatric research, and
it was used here in the way shown to be the most valid.
In Study II, two diagnostic interviews were used, SCAN (Wing et al., 1990) and SCID (First
et al., 2002), with both generating DSM-IV axis I diagnoses. However, minor differences
between these interviews could slightly affect the prevalences of single diagnostic
groups. In BD-MDD comparisons, some criteria modifications to assure comparability on axis
II were necessary because of the different versions of the SCID-II (Spitzer et al., 1990a;
First et al., 1997) used. Current alcohol dependence instead of total substance use
disorders was included in total axis I comorbidity, and modifications lowered total axis
II comorbidity and the prevalence of borderline personality disorder in BD by 2-3%. The
reliability of comorbid diagnoses was not evaluated.
8.2.4 Effect of current phase
Rating in an acute phase was done deliberately to investigate the persistence of comorbid
disorders, duration of index phases, and effect of index phase on outcome in follow-up.
However, including the patients in an acute phase could have had some impact on the
results. Patients’ beliefs about self and insight into illness differ between different
phases of BD (Dell’Osso et al., 2002; Bentall et al., 2005), and this could affect
patients’ willingness to participate and the ability to report symptoms objectively. In
addition, a current illness phase affects comorbidity ratings; for example, patients often
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deny symptoms while in a manic state (Dell’Osso et al., 2000), and depression and anxiety
seem to be related (Gaudiano and Miller, 2005). However, patients were met twice, and
comorbid disorders were assessed in a later subacute phase. In Study II, also depressed BD
and MDD patients were compared, and in the regression models, adjustments were made for
current illness phase. It should be emphasized that the diagnoses of personality disorder
were based on multiple sources of information and a longitudinal view of patients’
functioning during euthymic phases, not on current behavior. Despite our best efforts,
however, one cannot totally exclude the possibility that the current state might have
colored the perception of personality. Compared with studies of strictly euthymic patients
(Peselow et al., 1995; Ucok et al., 1998; Kay et al., 1999; Colom et al., 2000; Vieta et
al., 2000; Vieta et al., 2001; Brieger et al., 2003; George et al., 2003), the overall
level of axis II comorbidity here was intermediate. The study design was constructed as
closely as possible to the situation where a clinician meets mood disorder patients during
the acute phase.
8.2.5 Life chart and definitions of outcome
The life chart methodology is generally accepted as part of follow-up studies of BD.
However, the aim was to assess the compatibility of life chart phases with DSM-IV
criteria, which are part of everyday clinical practice and known to all clinicians. Thus,
the graphic life chart used in this study is similar but not identical to the Longitudinal
Interval Follow-Up Evaluation (LIFE) or NIMH life chart methodology used in other
prospective studies reporting separately on both BD types I and II (Tondo et al., 1998;
Dittmann et al., 2002; Judd et al., 2003b; Judd et al., 2003c; Post et al., 2003; Joffe et
al., 2004). This kind of graphic life chart was planned and used in the VDS (Melartin et
al., 2004). Similar to LIFE, change points in the psychopathologic state were inquired
about using probes related to important events. Unlike with LIFE, in the interview the
life chart was made directly comparable with DSM-IV criteria, and the patients’ follow-up
time was classified into periods of four DSM-IV phases of BD (major depression, mania,
hypomania, mixed episode) plus depressive mixed states, full remission with no symptoms of
phases, and partial remission when criteria for neither mood episode nor full symptomatic
remission were fulfilled. The life chart was constructed in the two follow-up interviews
based on patients  report, all available patient records, and other informants when
needed. As in any study not based on daily prospective mood ratings (Judd et al., 2003b;
Judd et al., 2003c), that the underreporting of some milder illness phases, such as short
hypomanic or depressive mixed episodes, could not be excluded. However, there is unlikely
to be any bias in the comparison of BD I and II in this respect.
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8.3 General characteristics of the cohort compared with other
cohorts with bipolar patients
The JoBS is the first clinical cohort study based on systematic screening for BD among
psychiatric in- and outpatients within a geographically defined catchment area, and this
affects comparability with other cohorts in many aspects. It is noteworthy that a
considerable proportion of even BD I patients, mostly with mild manias but still
unequivocal functional impairment at work or in family roles, had not been hospitalized or
diagnosed. The cohort therefore represents a considerably larger proportion of actual
bipolar patients in psychiatric care than previous studies. While this study is more
representative of BD in psychiatric care than other naturalistic prospective studies on
BD, the results may not be directly comparable because of the high proportion of
clinically unrecognized or misdiagnosed patients, especially in BD II. However, the
proportion of unrecognized patients was equal to that of patients not receiving mood
stabilizing treatment in the CDS (Judd et al., 2003b; Judd et al., 2003c).
In this cohort, psychotic symptoms during the lifetime were present in half, but currently
in only 16%, of all patients. These proportions are low compared with other, tertiary care
samples (Benazzi and Akiskal, 2001; Suppes et al., 2001; Serretti et al., 2002a; Akiskal
and Benazzi, 2003; Judd et al., 2003b; Schneck et al., 2004). Polyphasic episodes were
common; nearly all (85.0%) BD I and II patients had had at least one polyphasic episode
during their lifetime. The number was higher among BD I patients, as also reported earlier
(Kilzieh and Akiskal, 1999). A polyphasic episode was currently present in 51% of
patients, corresponding to previous cross-sectional studies (Coryell et al., 1987;
Winokur and Kadrmas, 1989; Maj et al., 2002), in 36% following intake and 64% overall (at
baseline or continuing from intake). Rapid cycling was present at intake in 29% of
patients, in contrast to less than 20% in earlier studies (Coryell et al., 1994; Angst et
al., 2005), and during follow-up in 40%, on the upper border (15-38.2%) of other
prospective follow-up studies (Maj et al., 1994; Baldessarini et al., 2000; Tondo et al.,
2001; Coryell et al., 2003; Schneck et al., 2004; Kupka et al., 2005). Thus, in this
naturalistic cohort, both polyphasic episodes and rapid cycling were highly prevalent,
while prevalence of polyphasic episodes has not been reported comparably in previous
studies. Especially rapid cycling might to some extent reflect factors related to
treatment.
In the follow-up of the JoBS cohort, 10% of BD II patients (9.9% of the 101 BD II patients
in the original sample, 11.8% of the 85 followed up for 18 months) converted to BD I
during the 18-month follow-up due to a manic (N=7) or mixed (N=3) episode; this is a
higher proportion than the 1-2% per year in longer follow-ups (Coryell et al., 1995; Angst
et al., 2005).
75
8.4 Clinical differences between bipolar I and II patients
The difference in current psychotic features between BD I and II (22.2% vs. 10.9%) was
less marked than that reported in a private clinic sample (80.9% vs. 5.6%) (Serretti et
al., 2002a), in a large sample of hospitalized depressive patients (62.4% vs. 21.9%)
(Benazzi and Akiskal, 2001; Akiskal and Benazzi, 2003), or in the CDS (54.8% vs. 18.3%)
(Judd et al., 2003b). Lifetime prevalences (67.8% vs. 33.7%) were slightly more similar to
results from other studies, 67% vs. 23% in the Stanley cohort (Suppes et al., 2001), and
56% vs. 14% in the STEP-BD (Schneck et al., 2004), the differences being greater in BD II.
Despite somewhat different clinical pictures, BD I and II did not differ significantly in
terms of comorbidity profile (McElroy et al., 2001; Suppes et al., 2001; Dittmann et al.,
2002; Judd et al., 2003b). This was true even regarding anxiety disorders, a finding that
is supported by many (McElroy et al., 2001; Suppes et al., 2001; Dittmann et al., 2002)
but not all (Henry et al., 2003; Judd et al., 2003b) comparative studies. In contrast, the
current index phase of BD strongly affected comorbidity, with axis I prevalences highest
in patients with a current mixed or mixed depressive episode and lowest in a (hypo)manic
episode (Dell’Osso et al., 2000). Although anxiety disorders were associated with
depressive or mixed phases, the ratio of current vs. lifetime comorbidity still seemed
high. Thus, as also reported earlier (Bauer et al., 2005a), anxiety disorders appeared
rather chronic, whereas the prevalences of distinct and total substance use disorders were
currently only one-third of lifetime prevalences, suggesting a more episodic nature. It is
also noteworthy that among bipolar patients some comorbid disorders cluster together
(McElroy et al., 2001; Boylan et al., 2004; Simon et al., 2004a; Bauer et al., 2005a),
with patterns similar to those in MDD (Melartin et al., 2002). Only a few patients had,
for instance, current alcohol use disorder alone, whereas anxiety disorders were the most
common as a single disorder. Axis I and II disorders also frequently coexisted. The marked
cross-sectional and longitudinal complexity of not only the mood disorder per se, but also
the concurrent disorders is a major challenge for clinicians.
8.5 Differences in comorbidity between bipolar disorder and major
depressive disorder
Both unipolar and bipolar mood disorders appear to be highly comorbid, but their profiles
of comorbidity are somewhat different. Overall, a current axis I comorbidity was more
prevalent in MDD than BD (70% vs. 57%). In the MDD patients of the VDS, the prevalences
were convergent with those previously reported, the prevalence of personality disorders
being somewhat lower and that of alcohol disorders being higher than the weighted means
reported elsewhere (Melartin et al., 2002). In the bipolar cohort, the prevalence of any
comorbidity on axis I was relatively high (McElroy et al., 2001; Simon et al., 2004a), and
on axis II (42.9%) intermediate compared with clinical studies of euthymic phase patients
(Peselow et al., 1995; Ucok et al., 1998; Kay et al., 1999; Colom et al., 2000; Vieta et
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al., 2000; Vieta et al., 2001; Brieger et al., 2003; George et al., 2003). This is the
largest clinical study reporting differences in anxiety and the first to examine
differences in alcohol dependence and eating disorders between BD and MDD. In line with
the previous literature, MDD patients had more anxiety disorders (Pini et al., 1997;
Yerevanian et al., 2001), while BD had more panic disorders (Chen and Dilsaver, 1995b;
Simon et al., 2003). Panic disorder and posttraumatic stress disorder were especially
prevalent in BD II. The similarity of prevalences of alcohol dependence was unexpected
(Regier et al., 1990; Angst, 1998; Cassidy et al., 2001b; de Graaf et al., 2003). However,
for methodological reasons, a possible difference in abuse cannot be excluded.
As hypothesized, the three clusters on axis II appeared differently distributed between
MDD and BD. Unlike previous reports on inpatients, in which MDD had more axis II
comorbidity (Rossi et al., 2001; Schiavone et al., 2004), no significant differences were
found in total prevalences of axis II disorder. However, more borderline personality
disorder was found among BD than MDD patients, which is in accordance with one outpatient
(Benazzi, 2000) but not inpatient(Rossi et al., 2001; Brieger et al., 2003; Schiavone et
al., 2004) studies. Furthermore, among BD patients, borderline personality disorder was
associated with substance use disorders, anxiety disorders, and cluster A personality
disorders, showing "complex comorbidity" as reported in an earlier study by Zanarini et al.
(Magill, 2004). Also, BD patients seemed to have eating disorders more often than those
with MDD. In contrast, phobic anxiety disorders were associated with cluster B and C
personality disorders among MDD patients but not among BD patients. Overall, the findings
are convergent with the idea that the temperamental profile underlying clusters of
personality disorders might be more concentrated in cluster B in BD, but broader in MDD,
including more clusters C and A. Finally, in line with a previous report (Henry et al.,
2003), no evidence was found for the theory that increasing any aspect of severity would
markedly increase overall comorbidity.
8.6 Recognition of bipolar disorder
This is the first study where psychiatric patients were first screened and then formally
diagnosed to include clinically recognized and unrecognized BD. Underrecognition of BD was
even more evident than expected from indirect sources (Lish et al., 1994; Ghaemi et al.,
1999; Ghaemi et al., 2000; Hirschfeld et al., 2003b); the extent in secondary care has not
been investigated using structured diagnostic tools. Surprisingly, as many as 26% of
bipolar I cases had remained undiagnosed. Long delays both in seeking treatment and in
diagnosing BD, as previously reported (Lish et al., 1994; Hantouche et al., 1998; Tondo et
al., 1998; Ghaemi et al., 1999; Ghaemi et al., 2000; Goldberg and Ernst, 2002; Baethge et
al., 2003; Baldessarini et al., 2003; Hirschfeld et al., 2003b; Morselli and Elgie, 2003),
emerged. The former largely explained the latter, but the delay in achieving a correct
diagnosis in treatment was still considerable.
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Correlates of unrecognized BD were also reported. Two previous studies surveyed reasons
for misdiagnosis, but the current and previous diagnoses plus reasons for misdiagnosis
were based on patient report only (ten Have et al., 2002; Hirschfeld et al., 2003b). Some
studies have estimated prevalence of misdiagnosis using the MDQ screen in case definition.
Although the MDQ is not a diagnostic tool (Zimmerman et al., 2004; Phelps, 2006),
diagnoses were made with diagnostic interviews only in one study (Hirschfeld et al.,
2005), which did not report predictors of misdiagnosis. Our findings are in line with
previous studies where women (Lish et al., 1994; Baethge et al., 2003; Baldessarini et
al., 2003; Hirschfeld et al., 2003b) and BD II patients (Akiskal et al., 2003; Baethge et
al., 2003; Baldessarini et al., 2003) often remained undiagnosed or were diagnosed only
after a longer delay. Longer delay was correlated with less severe forms of BD (Baethge et
al., 2003; Baldessarini et al., 2003) and lower age at onset (Goldberg and Ernst, 2002).
The findings suggest that BD I is better diagnosed largely due to the manic and psychotic
phases of illness leading to hospitalizations, whereas BDI patients who are not
hospitalized or have better functional status more often are misdiagnosed. BD II, by
contrast, does not lead to the dramatic contacts with healthcare that are typical of BD I.
These patients seem to instead be treated as outpatients with a diagnosis of unipolar
major depressive disorder, without attention to intermittent hypomanic phases, and only
receive a correctl diagnosis after years in treatment. This is somewhat understandable
since the first episode of BD is most often depression (Lish et al., 1994; Tondo et al.,
1998; Morselli and Elgie, 2003); BD II patients, in particular, spend most of their time
in depression (Judd et al., 2003a) and have more depressive episodes before the first
hypomania (Tondo et al., 1998). Although the role of the patient was not investigated
here, it seems to be important, especially in BD II (ten Have et al., 2002; Hirschfeld et
al., 2003b), in which the patient may not perceive hypomanic phases as disturbing or
pathological, and may in fact view them as periods of improved functioning (Judd et al.,
2005). Overall, therefore, it seems that at least partly different processes lead to
correct diagnosis of BD I and BD II, the former diagnosis occurring sooner in hospitalized
phases of the illness, the latter occurring as a function of time as an outpatient.
8.7 Differences in outcome between bipolar disorder I and II
Overall, BD II patients were more chronically ill; they spent a greater proportion of time
ill and in depressive states, more time in partial remission, and less time in full
remission. The finding that BD II patients did spend more time depressed in follow-up is
in line with the CDS cohort where more BD II than I patients were not receiving mood
stabilizing treatment. Other studies where treatment was more strictly controlled showed
no differences between BD I and II (Post et al., 2003; Joffe et al., 2004). BD I patients
did not spend more time in manic/hypomanic or mixed/depressive mixed states, unlike in
some other studies (Judd et al., 2003b; Judd et al., 2003c; Joffe et al., 2004), perhaps
because our study was the only one to include patients with hypomanic and depressive mixed
phases at intake. Two of the three possible explanations for a depressive picture were not
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true: depressive phase in BD I and II had the same duration, as reported earlier (Tondo et
al., 1998), and the frequency of depressive phases was the same in BD I and II. However,
BD II patients more often had at least one new depressive phase (Judd et al., 2003b), and
the proportion of depressions among new phases was higher. Thus, the difference between BD
I and II was the more depressive course of BD II due to the higher proportion of
depressions among the new phases.
This study is unique in that the effect of patient sampling and several confounding
factors that might influence the difference between BD I and II could be investigated. The
patients were sampled during an acute phase, reflecting natural differences in proportions
of all phases between BD I and II. The effect of index phase on outcome was evident in
several ways. In line with previous studies (Keller et al., 1993; Coryell et al., 1998;
Tondo et al., 1998; Judd et al., 2003b), a depressive phase lasted longer than other
phases, more often ended in residual symptoms, and if full remission was achieved, a
slightly longer time was needed. At intake, depression was equally prevalent in BD I and
II, and when only the depressive patients were compared, no differences in outcome between
BD I and II were detected. However, the differences in the prevalence of other index
phases were significant; the existence of manic phases, in particular, might partly
explain the differences in outcome. A manic phase was most likely to end and stay in full
remission; patients with a manic index phase had the lowest number of new phases and spent
two times longer being euthymic than those with a depressive index phase.
Several potential confounding factors (age, gender) and other factors known to correlate
with outcome (axis I and II comorbidity, duration of illness, age at onset, psychotic
symptoms) were taken into account. For instance, a manic index phase was also correlated
with better recognition of the disorder and receiving mood stabilizing treatment (Keller
et al., 1993; Coryell et al., 1998; Nolen et al., 2004). However, the higher proportion of
time depressed in BD II was evident even after controlling for these factors. Treatment
was not the main focus of this naturalistic study, and only acute-phase treatment was
analyzed here, but some interesting findings did appear. When only the recognized or
adequately treated patients were compared, BD II was more chronic, resembling the results
of the CDS (Judd et al., 2003b). Surprisingly, no differences in the principal outcome
measures were found according to clinical diagnosis or acute-phase pharmacotherapy in BD
II, a finding clearly different from BD I. Overall, the course of BD II tends to involve a
higher proportion of depressive phases with a poorer outcome, whereas manic phases in BD I
more often evolve into sustained full remission and better outcome. In theory, this could
in part be explained by manic phases leading to better recognition of BD and treatment. In
addition, the available treatments for bipolar depression, particularly for BD II, might
be less effective, at the very least opinions about the optimal treatment are varied
(Hadjipavlou et al., 2004). However, based on these results, it is unlikely that the more
depressive course of BD II is only due to the confounding effects of clinical diagnosis or
treatment.
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8.7.1 Depressive mixed phases
At intake, a depressive mixed phase was currently prevalent in 25.7% of BD II patients. A
current mixed episode in BD I was evident in 16.7% of cases, a figure lower than in
studies with hospitalized manic patients (Marneros, 2001a; Sato et al., 2002;
Gonzalez-Pinto et al., 2003; Berk et al., 2005) This is the first follow-up study to
include patients with depressive mixed index phases. Thus, it is interesting that BD I and
II equally often had new depressive mixed phases, that the durations of new mixed and
depressive mixed phases were similar, and that no statistically significant difference
between BD I and II was noted in the proportions of time in mixed and depressive mixed
phases when these states were considered together. Mixed and depressive mixed phases
seemed more similar to each other than manic and hypomanic phases in predicting outcome.
8.8 Contributions to the validity of distinction of bipolar
disorder I and II
Several demographic factors, clinical history, symptom profiles, diagnostic stability,
differences in comorbidity and outcome, and response to treatment (only grossly) were
evaluated, all of which can be used to ascertain the validity of distinguishing between BD
I and BD II. A clear difference between these two was found in outcome; BD II had a more
depressive course. This was evident even after controlling for differences between BD I
and II in correct clinical diagnosis and adequate treatment as well as other potential
confounding factors. Surprisingly, no difference in outcome between clinically diagnosed
and undiagnosed BD II patients or adequately and inadequately treated BD II patients was
evident. Since treatment was not the main focus of this naturalistic study and adequacy of
treatment was not evaluated in terms of patient compliance or laboratory tests, for
instance, this cannot be seen as evidence of a difference in treatment response of BD I
and II. It suggests, however, that separate cohorts of BD I and II are needed in treatment
trials. The clinical usefulness of treating BD I, by contrast, is well established based
on the literature and this study; with treatment, the outcome is clearly better.
Strikingly few other clinical differences between BD I and II were evident. Most of the
differences (hospitalizations, psychotic features, severity of symptoms) arise from the
definitions of diagnostic criteria. Only minor differences were evident in comorbidity
between BD I and II.
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Diagnostic stability was good; 10 BD II patients switched to BD I in the 18-month
follow-up. The interrater reliability in the JoBS was excellent also in distinguishing BD
I and II, but the proportion of clinically undiagnosed patients, especially BD II
patients, was alarmingly high. The clinical reliability of the diagnostic categories could
be questioned; however, more attention should be focused on improving the diagnostic
skills and resources of clinicians rather than questioning the validity of BD II as a
diagnostic category. The results suggest that clinicians find it more difficult than
researchers to accept the concept of BD II. One way to explain this could be that
clinicians have a prototype view of BD in general that best corresponds to BD I.
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9. CONCLUSIONS AND FUTURE IMPLICATIONS
9.1 Conclusions
In the Jorvi Bipolar Study (JoBS), BD was poorly detected. In terms of resources in
psychiatric care and primary health care, the cities of Espoo, Kirkkonummi, and
Kauniainen, where the cohort was collected, are among the best in Finland. Thus, the
likelihood of bipolar patients being correctly and quickly diagnosed is probably even
smaller in other parts of the country. The results on recognition, comorbidity, and
outcome can be generalized also to other countries: the subjects are representative of
secondary care patients, and the findings of this study are in line with the previous
literature.
Some implications for the validity of categorical diagnoses of MDD and BD, as well as BD I
and II, were evident. Patterns of psychiatric comorbidity of BD and MDD are likely to
differ somewhat qualitatively. BD I and II patients appear to differ little in terms of
comorbidity, and the clinical differences in prevalence of psychotic features and
hospitalizations reflect the diagnostic criteria of the disorders. However, the
differences in outcome are clear and not explained solely by differences in mood at intake
or differences in recognition or treatment. BD II compared with BD I patients more often
had any depressive phase, higher proportions of depressive phases among all phases, and
higher frequency of these phases during the follow-up, whereas duration of the depressive
phases per se was equal. As a result, BD II patients spent about 40% more time depressed
than BD I patients in medium-term follow-up.
Effect of the type of current phase at evaluation is evident in several ways. The
prevalence of psychiatric comorbidity is strongly related to the current illness phase of
BD, the depressive and mixed patients having the highest prevalences of anxiety disorders.
If the patient is currently manic or psychotic, the BD is correctly recognized in most
cases, but if the patient is seeking help for a depressive phase, all too often only this
current status serves as the basis for diagnosis and treatment. A depressive phase
predicts the poorest outcome in terms of several outcome measures after medium-term
follow-up.
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9.2 Clinical implications
Recognition of BD is a major challenge even for psychiatrists. The evaluation of diagnosis
and treatment of BD should be done in psychiatric care. Greater diagnostic precision
concerning the type of mood disorder (MDD, BD I, or BD II) as well as in evaluating
comorbid disorders is essential for improving the quality of treatment, and thus, the
outcome and quality of life of patients. Instead of reliance on cross-sectional
presentation of illness, professionals should consider the longitudinal course when making
a diagnosis and planning treatment. Screening all depressive patients for BD is warranted
to identify patients needing immediate diagnostic evaluation of BD, and the clinical
diagnosis should be critically re-evaluated in case of treatment failure. Repeated
diagnostic evaluation with other informants and longitudinal follow-up of mood in
treatment are needed for every patient also to detect conversion from MDD to BD or from BD
II to BD I and the emergence of new comorbid disorders.
Evaluation of recovery should happen at several levels; syndromatic, symptomatic, and
functional recovery should be the target of professionals. Life chart methodology is a
valuable tool for the professional as well as for the patient for learning to identify the
type and course of illness at an individual level. Use of observer or self-report scales
measuring severity of depressive and manic symptoms as well as functional status and
suicidality is recommended to detect the longitudinal fluctuations in status. Repeated
systematic evaluation of diagnoses and status may serve as a tool for psychoeducation of
the patient, thus ensuring better compliance in treatment, and over time, increasing
disease control.
BD affects individuals and society at many levels. BD is a major public health problem and
is one of the most expensive disorders for society because of its recurrent and chronic
nature and high mortality. Psychosocial and functional disability fluctuates in parallel
with changes in affective symptom severity. Even subthreshold level symptoms are important
for functional outcome and must be carefully evaluated to improve consequences of the
disorder, including markedly increased healthcare use and costs, higher unemployment, work
impairment, increased work absenteism owing to illness, and thus, decreased work
productivity and lower annual income. It may take years to find the optimal combination of
treatments, biological as well as psychosocial, for individual patients. The response,
outcome, and side-effects of individual patients show the adequacy and suitability of
treatment. At the same time, individual patients have differing goals in life, and quality
of life is a subjective experience not directly correlated with symptomatic recovery.
If mood disorder patients could be optimally diagnosed and the number of BD patients in
treatment was twofold, this would have considerable consequences on psychiatric care. A
need for new resources is evident in planning future treatment facilities for psychiatric
patients. More time for the diagnostic evaluation of mood disorders is required, and a
large group of patients needs repeated evaluation of treatment response by a psychiatrist
and illness-specific psychosocial treatments. For instance, the disorder has a serious
impact on social relations of the patient, and patients’ experience of the quality of life
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is most dependent on social support. Thus, not only the patient but also the family needs
to be considered. Undiagnosed BD patients are known to need even more acute and long-term
psychiatric treatment than patients with a correct diagnosis.
The evaluation, treatment, and prevention of manic and especially depressive episodes
should be a special interest of clinicians. Also, the presence of mixed features should be
carefully evaluated in both BD I and BD II patients given that depressive mixed states are
at least as common among BD II patients as mixed episodes are among BD I patients. Both
depressive and mixed features worsen the outcome, affect the recommended treatment, and
increase the prevalence of suicidality.
9.3 Implications for future research
New challenges for research arise from patients without a clinical diagnosis not
representing the whole bipolar population and important clinical differences existing
between clinically diagnosed and undiagnosed bipolar patients. To truly reduce burden and
costs of BD, the clinical picture of previously unrecognized BD patients should also be
better known. To get a comprehensive picture of all bipolar patients, using a screen to
select patients is warranted. Also long-term randomized controlled trials on both drug and
psychosocial treatments should be carried out among ordinary BD patients with high
comorbidity and chronic course of illness to separate type II disorder. In addition to
efficacy of treatment, the effectiveness in every day medical practice should be
evaluated. This better takes into account the common noncompliance of patients and the
fact that the clinicians seldom prescribe medication as defined in the treatment
guidelines. Uncovering details on the reasons for noncompliance of patients as well as on
clinicians’ views tha lead to undiagnosed or inadequately treated BD is important for
improving the overall outcome of patients. More information about the true prevalence and
course of BD I and especially BD II is needed to plan healthcare resources to better
respond to the needs of affected patients.
The limits of mood disorders and comorbid disorders require further clarification and
validation. Both categorical and dimensional models of these disorders should be included
in the same studies, ideally combining clinical, familial, and genetic information. To
elucidate the relationship between mood disorders and comorbid disorders, more
longitudinal information is needed to determine whether the same patients have the same
profile of comorbidity when euthymic, and whether comorbid disorders differ in stability
during follow-up. It also remains open whether the comorbidity profile affects the type
and course of the current phase, and what specific effects different comorbidity profiles
have on the longitudinal course.
Research on the predictors of outcome is important to detect those patients who are most
vulnerable to poor outcome. Genetic, biological, developmental, and environmental risk
factors contributing to contracting a mood disorder, to having BD I or BD II, and to
determining the specific course of illness should be investigated simultaneously
controlling for interactions and confounding factors.
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